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1 INTRODUCTION 
1.1 Background: New aspects of anticancer drug discovery 
According to the National Cancer Institute (NCI) cancer is defined as a term for 
diseases in which abnormal cells divide without control, showing the potential to 
invade nearby tissues or to spread to other parts of the body through the blood and 
lymphatic systems.  
Evolving studies with several different targeted therapeutic agents are 
demonstrating that patients with genomic alterations of the target − including 
amplification, translocation and mutation − are more likely to respond to the therapy. 
Recent studies indicate that numerous components of the phosphatidylinositol-3-
kinase (PI3K)/Akt pathway are altered by amplification, mutation and translocation 
more frequently than any other pathway in cancer patients, with resultant activation 
of the pathway. This warrants exploiting the PI3K/Akt pathway for cancer drug 
discovery.1 
The Akt signaling pathway has been implicated in several cytoskeleton-mediated 
processes including the regulation of actin reorganization during vascular 
endothelial growth factor (VEGF)-induced migration of endothelial cells2 and 
blocking of ezerin, a cytoskeleton-plasma membrane linker protein which negatively 
regulates Akt activity to promote apoptosis.3 Activated PI3K generates 
phosphoinositides which stimulate 3-phosphoinositide-dependent protein kinase 1 
(PDK1) being attributed to phosphorylating T308 and possibly S473 on Akt.4 PDK1 
is ubiquitously expressed in human tissues5 and its mediation in the PI3K/Akt 
pathways has been closely linked with several cancer types,6 especially breast 
cancer.7-8 Uncontrolled activation of the Akt pathway leads to a deregulation in cell 
growth and overall survival, allowing for competitive growth advantage, metastatic 
competence and, as often found in breast cancer, therapy resistance.9 This 
pathway is therefore an attractive target for the development of novel anticancer 
agents.1, 9-10 
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In a recent inverse kinase screening assay looking for unexplored targets of newly 
derived substances, the PDK1 kinase was shown to be a target of the anticancer 
compound 6-bromo-indirubin-3’oxime (6BIO) − a synthetic derivative of the natural 
product indirubin − but not of 7-bromo-indirubin-3’oxime (7BIO) in endothelial 
cells.11 As PDK1 kinase activity is directly responsible for the initial phosphorylation 
step in the full activation of Akt, it can be hypothesized that 6BIO could specifically 
target the deregulated pathways involving Akt in tumor cells.  
 
Consequently, this preliminary study by Zahler et al.11 prompted the investigation of 
two indirubin derivatives, namely 6BIO and 7BIO, in cancer cells in this thesis. As 
6BIO, but not 7BIO, is able to bind to the PDK1 kinase with high affinity, the 
difference in target specificity will be used to demonstrate the essential role of Akt in 
metastatic tumor cells. Moreover, preliminary data will provide evidence of 6BIO’s 
ability to repress the invasive capacity of tumor spheroids in a confrontation assay 
with human fibroblast spheroids. 
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1.2 The role of natural products in treatment of diseases 
Natural products and compounds based on natural product structures are the single 
most prolific source of most drugs today.12-15 Over 100 natural product-derived 
compounds are currently undergoing clinical trials and at least 100 similar projects 
are in pre-clinical development. Most of these products are derived from plants and 
microbial sources as seen in Table 1.12, 16 Between 2005 and 2007, 13 natural 
product drugs were approved, five of which represent the first members of new 
classes of drugs.12-13   
 
Table 1.   Drugs based on natural products at different stages of development 
 
Throughout history, natural products have had an essential role in the treatment of 
diseases. Egyptian medicine dates back to 2900 BC, but the best known record is 
the “Ebers Papyrus”, which dates from 1500 BC and documents over 700 drugs, 
mostly of plant origin. Records documenting the uses  of approximately 1000 plant- 
derived substances in Mesopotamia date from around 2600 BC, and many are still 
used today for the treatment of ailments ranging from coughs and colds to parasitic 
infections and inflammation.17 Plants are of special note, with an extensive history 
in the treatment of cancer. It is reported by the World Health Organization (WHO) 
that over 3000 species of plants have been used in the treatment of cancer.18 A 
recent WHO survey of plant-derived pure compounds used as drugs in countries 
that contain WHO-Traditional Medicine Centers indicated that 80% of 122 
compounds from 94 identifiable plant species were found to be used for the same 
or closely related ethnomedical purposes worldwide.14, 19-20 These findings show 
that natural products have played an essential role in helping to define natural 
product sources used in contemporary medicines. 
Development stage Plant Bacterial Fungal Animal Semi-synthetic Total 
 
Preclinical 46 12 7 7 27 99 
 
Phase I 14 5 0 3 8 30 
 
Phase II 41 4 0 10 11 66 
 
Phase III 5 4 0 4 13 26 
 
Pre-registration 2 0 0 0 2 4 
 
Total 108 25 7 24 61 225 
 
Source: Harvey 2008, Pharmaprojects database (March 2008). 
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There are many historical examples in which the natural product has not just been 
the medicinal product, but has also helped to reveal a novel aspect of physiology. 
For example, Digitalis from foxglove enabled the elucidation of the role of sodium-
potassium-ATPase.12, 21 Furthermore, Taxol which surprisingly stabilizes micro- 
tubules during cell division rather than destabilizing them as Vinblastine does, 
allowed the establishment of structure–activity relationships for hundreds of semi-
synthetic analogues.22 By elucidating and understanding mechanism such as these, 
drug discovery can be specifically targeted towards deregulated systems in various 
diseases, especially cancers. 
 
1.3 Indirubins as anticancer compounds 
Indirubins are highly promising novel anticancer compounds derived from natural 
products which inhibit cyclin dependent kinases (CDKs) preferentially. CDKs are a 
family of small serine/threonine kinases that associate with cyclins and are 
generally known as the master regulators of the main transitions of the eukaryotic 
cell cycle.23 CDKs are often deregulated in cancer making them interesting targets 
for chemotherapeutics. Several recent indirubin derivatives have also been shown 
to interact with key members of pathways which are involved in the development of 
cancer including 3-phosphoinositide-dependent protein kinase 1 (PDK1), glycogen 
synthase kinase 3β (GSK3β), protein kinase C (PKC) isoforms, protein kinase A 
(PKA), and c-Src tyrosine kinase. These compounds are very promising candidates 
that need to be fully investigated, so that they can reach the clinic. 
 
1.3.1 History of indirubins 
Indigoids are a chemical family of bis-indoles based on indigo, indirubin and their 
collective derivatives. The family of indigoids has had a noteworthy pharmaceutical, 
historical and a substantial cultural impact.24-25 Indirubin is derived from a 
spontaneous non-enzymatic dimerisation of isatin and indoxyl, both of these 
precursors are found in various natural sources including marine mollusks, bacteria, 
indigo-producing plants, and is sometimes present in mammalian urine which is 
also known as “purple bag syndrome.”24-29  
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Danggui Longhui Wan is a traditional Chinese medicinal preparation which contains 
eleven herbal constituents used to treat various chronic diseases including chronic 
myeloid leukemia. Recent interest in the Chinese pharmacopeia has led to the 
discovery of the active herbal component of this mixture named Qing Dai or better 
known as indigo naturalis. It is the red colored byproduct 3, 2’ isomer indirubin and 
has found to be the main antileukemic component of this herb.28 Indirubin itself was 
described more than 30 years ago as a treatment for chronic myeloid leukemia.30 
Several research groups have intensively studied indirubins and some of their 
derivatives to try and elucidate their complex modes of action. Different members of 
the indirubin family act as potent inhibitors of CDKs,29 glycogen synthase kinase 3 
(GSK3),31-32 the aryl hydrocarbon receptor (AHR),26 the Src tyrosine kinase and the 
Stat3 transcription factor33 among other yet-undefined targets. 
Also, indirubins have been pursued in both animal and human studies. Membrane 
morphology of the surface of white blood cells of guinea pigs treated with indirubins 
has been reported to be altered.34 The absence of bone marrow toxicity and 
hematotoxicity was found in long term animal studies35-36 and reversible diarrhea 
and slight hepatotoxicity were seen over a 6 month study in dogs with indirubin 
doses up to 25 times higher than those used for treatment in humans.28, 36 
Indirubin itself is no longer in clinical use due to its poor water solubility, but a wide 
variety of derivatives have been chemically synthesized to optimize selectivity, 
solubility and efficacy against tumor growth.31 
 
1.3.2 6BIO and 7BIO: Specific derivatives of indirubins 
The lack of cellular uptake of indirubin is unfavorable and has led to a wide variety 
of modified derivatives in search of improved cellular membrane permeability. 
Introduction of an oxime group in position 3’ allowed the generation of β-glycosides 
linked through an ethylene ether bridge is a very promising approach into novel 
drugs with improved bioavailability as these substances tend to preferentially inhibit 
CDKs and other kinases.28  
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Crystal structures of CDK2, a kinase that is involved in cell cycle control, in complex 
with indirubin-3’-oxime (IO) have recently been published.29, 37 The interaction of the 
inhibitor with the ATP-binding site was characterized and the bent shape of 
indirubin ‘facial side’ complements the shape of the ATP-binding pocket.37 
Additionally, three derivatives, namely 5-bromo-indirubin-3’oxime (5BIO), 6-bromo-
indirubin-3’oxime (6BIO), and 7-bromo-indirubin-3’oxime (7BIO) − although 
incredibly similar on a structural level − have been reported to have significantly 
varied biological activities. Both 5BIO and 6BIO are reported to inhibit CDKs, GSK-
3β and other kinases,31 whereas 7BIO was shown to induce cellular death in a 
kinase-independent manner.38-39 
 
Figure 1.1:   2D Structure of indirubin derivatives 
 
Image adapted from Zahler et al.11 
 
6BIO (Figure 1.1) was reported by Meijer et al. in 200331 as a synthetic derivative 
from the natural product 6-bromoindirubin which was discovered as an active 
component extracted from the “Tyrian purple” dye produced from gastropod 
mollusks. It was described therein as a potent and selective inhibitor for GSK-3β. 
Co-crystal structures of 6BIO and GSK-3β as well as 6BIO and CDK2 were 
published showing 6BIO interacting within the ATP-binding pockets of these 
kinases.31  
Since this landmark paper, there have been just over 40 publications focusing on 
6BIO activity in neurons,32, 40 against bone loss,41 in liver tissues,42 in 
cardiomyocytes,43 as well as in Wnt and Stat3 signaling pathways.33, 42, 44-45  
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Quite recently the substance was used to expand stem cells and maintain their self-
renewal.45-47 As it is such a new compound, only a few of the kinase targets have 
been elucidated and further study is essential to fully understand its antitumor 
capabilities. 
Although nearly structurally identical to 6BIO, the substance 7BIO (Figure 1.1) has 
been reported to have a completely different mode of action as an antitumor 
compound relative to other reported indirubin derivatives.38 It was demonstrated to 
induce cellular death, possibly through necrosis or autophagy, rather than the 
typically studied indirubin targets of CDKs or GSK-3β.39. Very limited information on 
this substance has been published so far, and its modes of action are not well 
defined. 
 
1.3.3 Kinase screening with indirubin derivatives 
The basis for my thesis came from a recent report out of our lab in which several 
indirubin derivatives were investigated in a virtual kinase screening assay which 
was supported with an in vitro kinase assay.11 
The first assay was a digital inverse kinase screening assay against a database of 
approximately 6000 protein binding sites. Single compounds were docked into 
protein structures stored within the database, and the top 32 protein binding sites 
for each compound are shown in Table 2.  
The outcome of this assay indicates that both 5BIO and 6BIO show strong binding 
to their already defined targets (CDK2, CDK5 and GSK-3β), with several other 
major targets in the top 1% as potential targets (CSK2A, WEE1, CDC2H, RIFK and 
PDK1). Specifically, in the inverse screening assay, 6BIO seemed to target PDK1 
much more effectively than the other indirubin derivatives tested. These findings 
were briefly experimentally validated and 6BIO was shown to be the only potentially 
effective derivative as an inhibitor of PDK1. 
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Table 2.  Top 32 kinase structures targeted by indirubin derivatives  
 according to ligand docking 
 
(Table Source: Zahler et al. 200711) 
 
 
5 BIO     6 BIO     7 BIO     
PDB ID Kinase Score PDB ID Kinase Score PDB ID Kinase Score 
1pxo_CK7 CDK2 -8.878 1q41_IXM GSK3B -8.731 1waw_RIG CHIT1 -8.082 
1jvp_LIG CDK2 -8.472 2bhe_BRY CDK2 -8.617 1nb9_RBF RIFK -8.052 
1w0x_OLO CDK2 -8.456 1jvp_LIG CDK2 -8.497 2bqz_SAH SETD8 -7.821 
1e9h_INR CDK2 -8.390 1unh_IXM CDK5 -8.444 2bqz_SAH SETD8 -7.821 
1pkd_UCN CDK2 -8.352 1x8b_824 WEE1 -8.337 1jvp_LIG CDK2 -7.765 
1q41_IXM GSK3B -8.318 1pye_PM1 CDK2 -8.263 1x8b_824 WEE1 -7.719 
1fin_ATP CDK2 -8.217 1r78_FMD CDK2 -8.097 1m6w_12H ADHX -7.689 
1x8b_824 WEE1 -8.160 1e9h_INR CDK2 -7.983 1zkk_SAH SETD8 -7.684 
1pxp_CK8 CDK2 -8.108 1waw_RIG CHIT1 -7.983 1q91_DPB NT5M -7.671 
1pye_PM1 CDK2 -8.076 1waw_RIG CHIT1 -7.983 1tbm_IBM PDE9A -7.671 
1vyw_292 CDK2 -8.054 1oky_STU PDK1 -7.975 1s1r_NAP AK1C3 -7.664 
1waw_RIG CHIT1 -8.050 1fin_ATP CDK2 -7.967 1s1p_NAP AK1C3 -7.654 
1xbc_STU KSYK -8.003 1nb9_RBF RIFK -7.897 1q41_IXM GSK3B -7.531 
1xp0_VDN PDE5A -7.962 1aq1_STU CDK2 -7.885 1v40_O16 PTGD2 -7.531 
1nb9_RBF RIFK -7.922 1dig_L37 C1TC -7.881 1w0x_OLO CDK2 -7.515 
1sm2_STU ITK -7.839 1xbc_STU KSYK -7.874 1r0p_KSA MET -7.482 
1dig_L37 C1TC -7.770 1dia_L24 C1TC -7.827 1pjk_ANP CSK21 -7.474 
1aq1_STU CDK2 -7.742 1udt_VIA PDE5A -7.802 1n6a_SAM SETD7 -7.431 
1oky_STU PDK1 -7.729 1tbf_VIA PDE5A -7.784 1x97_FIR ALDR -7.369 
1u59_STU ZAP70 -7.724 1y6a_AAZ VGFR2 -7.768 1z57_DBQ CLK1 -7.319 
1oit_HDT CDK2 -7.674 1q91_DPB NT5M -7.747 1mlw_HBI TPH1 -7.309 
1pjk_ANP CSK21 -7.673 1oiq_HDU CDK2 -7.726 1pwm_FID ALDR -7.297 
1tbf_VIA PDE5A -7.628 1di8_DTQ CDK2 -7.717 1uyf_PU1 HS90A -7.295 
1h1s_4SP CDK2 -7.621 1urw_I1P CDK2 -7.707 1p2a_5BN CDK2 -7.257 
1y6a_AAZ VGFR2 -7.597 1xg5_NAP DHR11 -7.698 1dig_L37 C1TC -7.220 
1xu7_NDP DHI1 -7.544 1uu7_BI2 PDK1 -7.698 1el3_I84 ALDR -7.215 
1dia_L24 C1TC -7.539 1jqe_QUN HNMT -7.690 1cea_ACA PLMN -7.171 
2bqz_SAH SETD8 -7.523 1uho_VDN PDE5A -7.657 1xqh_SAH SETD7 -7.168 
1xu9_NDP DHI1 -7.518 2bqz_SAH SETD8 -7.646 1ish_ENP BST1 -7.160 
1pwm_FID ALDR -7.509 2biy_ATP PDK1 -7.610 1pye_PM1 CDK2 -7.137 
 
 
Ligands were docked to the structures in the Protein Data Base, with the PDK1 kinase 
highlighted in gray. Abbreviations under PDB ID: STU (staurosporine), IXM (indirubin-3'-
monoxime), and ANP (phosphoaminophosphonic acid-adenylateester). All kinase structures 
are listed with most favorable docking scores in descending order.  
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Additionally, Figure 1.2 depicts virtual examples of the docking assay.11 The images 
indicate that indirubin 3’-oxime (IO) shows a strong binding preference for CDK2 in 
Figure 1.2(B) and the ability to bind to CDK5 in Figure 1.2(A). 6BIO is shown 
docked to PDK1 in the presence of staurosporine in Figure 1.2(C) or with PDK1 
alone using VDW-Sphere imaging in Figure 1.2(D). Moreover, 7BIO is docked to 
PDK1 with the LY333531 inhibitor, but the binding is not optimal (Figure 1.2(E)).    
 
Figure 1.2:   Docking assay results 
 
A) Indirubin 3’-oxime (thick, atom colored sticks) redocked into a CDK5 structure in complex with 
indirubin 3’-oxime. The resulting score leads to rank 11 for this structure among the kinases and 36 
in the complete set of complexes. The model is in perfect agreement with the typical interaction motif 
of two or three hydrogen bonds (shown as dashed blue lines) to the protein backbone (shown in the 
background of this picture). The conformation of indirubin 3’-oxime as found in the PDB structure is 
shown as thin cyan sticks and shows nearly perfect agreement with the model. B) Indirubin 3’-oxime 
(thick, atomcolored sticks) docked into a CDK2 structure. This complex has rank 1 among the 
kinases and rank 5 in the complete set. The model is in perfect agreement with the typical interaction 
motif of two or three hydrogen bonds (shown as dashed blue lines) to the protein backbone (shown 
in the background of this picture). The ligand originally contained in the X-ray structure is shown as 
thin cyan sticks for comparison. (C) 6-bromo-inidirubin 3’-oxime model into PDK1 with bound 
inhibitor staurosporine. The figure shows the good agreement with the backbone hydrogen bonding 
motif. (D) The solvent accessible surface of the binding pocket of PDPK1 together with the VDW-
Sphere depiction of 6-bromo-inidirubin 3’-oxime indicate that the binding pocket can easily 
accommodate the halogen. (E) 7-bromo-inidirubin 3’-oxime docked into PDK1 with bound inhibitor 
LY333531. The binding motif is in principle present; however, the geometry of the hydrogen bonds to 
the backbone is not optimal.  
Image adapted from Zahler et al.11 
 
Finally, based on the results from the virtual kinase screening assay, an in vitro 
PDK1 kinase assay was performed. Figure 1.3 shows the results of a collaborative 
effort between our lab, the Bioinformatics group at the Department of Computer 
Science at LMU and ProQinase GmbH.11 The graphs indicate that there is a dose-
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dependent relationship with PDK1 kinase and that 
the most optimal of the four indirubin derivatives 
Figure 1.3:   In vitro kinase assay result
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1.4.1 Standard treatments for metastatic cancer  
Initially, the surgical removal of tumors or use of radiotherapy can provide or even 
cure some cancers. These therapies are limited in that they are only capable of 
targeting local or regional tumors. Metastatic cancer, however, requires the use of 
cytotoxic chemotherapies, targeted therapies or therapies tailored to hormone 
imbalance to treat the tumors which have spread throughout the body. While 
sometimes effective, these treatments can be associated with severe toxic side 
effects, or the cancer cells themselves can become resistant to the chemo-
therapeutic agents.  
Current methodologies of treatment of metastatic cancer can be broken down into 
three major chemotherapeutic categories in combination with standard surgical and 
radiotherapeutic techniques:52  
- Cytotoxic chemotherapies - include the well-known substances of Paclitaxel, 
Doxorubicin and 5-Fluorouracil. These substances are able to disrupt cellular 
functions in dividing cancer cells.53  
 
- Targeted therapies – include Bevacizumab or Trastuzumab, both of which 
are monoclonal antibodies capable of targeting specific over-expressed 
oncogenes in metastatic tumor cells.54 These forms of therapies are now 
becoming more popular due to their success rates and specific targeting of 
tumor cells. 
 
- Hormonal therapies – include substances such as Raloxifene or Fulvestrant. 
This form of therapy works only in the specific case of cancers that grow in 
the presence of estrogen (ER) or progesterone (PR). They are most often 
used for ER+ or PR+ tumors.55  
 
Each of these treatment categories has varied levels of success rate dependent on 
tumor type and any previous treatments. In many cases the success rates are 
rather low and often associated with very serious secondary effects making the 
search for anti-metastatic chemotherapeutics a top priority in the fight against 
cancer. 
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1.4.2 Regulation and signaling of tumor cell migration 
To achieve metastasis, cancer cells must evade or co-opt multiple rules and 
barriers. Therefore metastatic signaling is an extremely complex process of events 
which cancer cells undergo. Several discrete steps are discernible in the biological 
cascade of metastasis: loss of cellular adhesion, increased tumor cell motility and 
invasiveness, entry and survival in circulation, exit into new tissue, and eventual 
colonization of a distant site.56 Figure 1.4 depicts the currently accepted model of 
metastatic tumors. 
 
 
Figure 1.4:   Basic overview of metastatic signaling 
 
Cells from the primary tumor gain migratory properties and invade into the surrounding stroma in the 
initial phases of the metastatic cascade. Following circulation, the cells must actively extravasate 
into the target organ. Once in the new location, the cells must activate the surrounding stroma and 
either persist in a dormant state or die. 
Image adapted from Dr. Y Shiozawa57 
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During cellular migration the initial step is the polarization of the cell using actin-
dependent protrusions found at the leading edge of the cell, where the lamellipodia 
and filopodia are formed. Next, integrin clustering at new adhesion points attach to 
the substratum are formed under the leading edge during the cellular extension 
phase. Ras-related C3 botulinum toxin substrate 1 (Rac1), a member of the Rho 
family of GTP-binding proteins, is activated and contributes to the polarity and 
shape of the migrating cell. This phase is followed by the translocation of the 
nucleus and the cell body towards the front of the cell by the actomyosin-based 
contraction forces linked to the integrin clusters found at the focal adhesions. Finally 
in the retraction phase, the retraction fibers draw the rear of the cell forward in 
conjunction with the disassembly of the focal adhesions now found at the rear of the 
cell as seen in Figure 1.5. 
 
Figure 1.5:   Cell migration 
 
Image of cellular migration depicting the cell polarization at which focal contacts form at the leading 
edge of the cell. Protrusion and new focal adhesion formation at the leading edge of the cell and  
rear retraction and adhesion disassembly at the rear of the cell.  
Image adapted from Wehrle-Haller 2003.58  
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1.4.2.1 The actin cytoskeleton 
The actin cytoskeleton is essential in regulating the basic cellular infrastructure as 
well as its key role in motility.59  The three main types of cytoskeletal proteins 
include microtubules, intermediate filaments and actin filaments.  
The first step in migration is polarization of the cell. During this step the filopodia 
and lamellipodia, which are actin-dependent protrusions, begin to form structures at 
the leading edge of the cell. Filopodia are the thin projections of plasma membrane 
supported by actin bundles. Lamellipodia are the broad, ruffle-like membrane 
protrusions observed at the leading edge of cells during movement. Integrins are 
responsible for cellular attachment to and movement along the extracellular matrix 
(ECM), which causes reorganization of the actin cytoskeleton.60-61 On ligation to the 
ECM, integrins cluster in the plane of the membrane and recruit various signaling 
and adaptor proteins to form structures known as focal adhesions (FAs) which also 
serve as attachment sites for recruitment proteins and large bundles of actin 
filaments called stress fibers.62  
Actin is a 43-kilodalton (kDa) protein which forms actin filaments (F actin) through a 
complex process of polymerization and depolymerization. These filaments elongate 
through the reversible addition of monomers to either end, with the plus end 
elongating at a faster rate than the minus end. This effect occurs because ATP-
actin dissociates less readily than adenosine diphosphate (ADP)-actin. Due to this 
variance in rate, there is a significant variance in the critical concentration of 
monomers at either end, resulting in what is known as treadmilling. Treadmilling is 
an essential part of the dynamic assembly and disassembly of F actin filaments 
which is required for both structure and movement.59, 63  
Figure 1.6 depicts an actin model of cellular migration. Lamellipodia and filopodia 
are shown on the leading edge of the cell. The contraction of the F actin stress fiber 
network drives the cell forward in response to integrin-mediated signaling at the 
FAs. Key regulators control the actin-binding proteins, regulating the necessary 
assembly, disassembly and cross-linking of actin filaments.58-59, 63 Members of the 
Rho subfamily of small GTP-binding proteins (GTPases) in conjunction with focal 
adhesions and integrins play key roles in cancer cell motility by regulating the 
INTRODUCTION 15 
 
 
organization of the actin cytoskeleton, thus controlling a variety of cell processes, 
including cell motility, cell adhesion and cytokinesis.58, 64-66 
 
Figure 1.6:   Cell motility model 
 
Lamellipodia form at the leading edge upon integrin signaling. Focal adhesions are formed and F 
actin stress fibers contract to drag the cell forward in conjunction with the disassembly of the 
adhesions at the rear of the cell. The cell is then dragged in the direction of migration. Integrins are 
endocytosed and recycled to the leading edge of the cell during movement. PI3K is activated in 
response to growth factors leading to the recruitment of active Akt to the leading edge where the 
lamellipodia are further induced by Rac1.  
Image adapted from Jiang 2009.64 
 
 
Furthermore, integrins are responsible for cellular attachment to and movement 
along the extracellular matrix (ECM), which causes the reorganization of the actin 
cytoskeleton.60-61 On ligation to the ECM, integrins cluster in the plane of the 
membrane and recruit various signaling and adaptor proteins to form structures 
known as focal adhesions which also serve as attachment sites for recruitment 
proteins and large bundles of actin filaments called stress fibers.62  
1.4.2.2 Akt as a cellular key regulator 
Akt, also known as protein kinase B, is a 57 kDa serine/threonine kinase which has 
recently been shown to be an essential regulator of the actin cytoskeleton during 
cellular migration.67 Additionally, Akt is known to play a crucial role in cell survival, 
growth, proliferation, angiogenesis and cellular metabolism as well as in cell 
migration and invasion.6, 67-69  
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Growth factors are thought to be necessary for the full activation of Akt. These 
growth factors bind to receptors and activate the receptor-associated PI3K which 
phosphorylates PtdIns-3,4-P2 to PtdIns-3,4,5-P3. The hydrophilic portion of the 
PtdIns-3,4,5-P3 binds to the PH domain of Akt, whereas the hydrophobic part of the 
PtdIns-3,4,5-P3 interacts with lipid bilayer of the membrane thus translocating Akt to 
the plasma membrane. This translocation brings it into the proximity of both the 
PI3K-dependent kinase 1 (PDK1) and PDK2 which, in the case of PDK1, is thought 
to be constitutively active and mutually co-localizes with the PtdIns-3,4,5-P3 to the 
plasma membrane.70 Akt thereby undergoes phosphorylation at two sites, first at 
the activation loop (T308) and then at the carboxy-terminal tail (S473). 
Phosphorylation at T308 is attributed solely to the action of PDK1. The kinase that 
phosphorylates Akt at S473 (PDK2) has been discussed for many years and has 
been attributed the mTOR complex, PDK1, Akt itself or other members of the AGC 
family.71-74 Akt is considered fully activated only when both the T308 and the S473 
have been phosphorylated (Figure 1.7).  
 
Figure 1.7:   Model of Akt and Akt activation 
 
PtdIns interact with the PH domain of Akt to promote the translocation of Akt from the cytosol to the 
plasma membrane. PDK1 interacts with the C-tail and phosphorylates T308. The S-residue at 
position 473 is phosphorylated by PDK2. This final form of Akt is fully active and can phosphorylate 
target proteins.  
Image adapted from Grille 2003.75 
 
 
 
 
PDK1
PDK2
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Upon complete activation, Akt is released back into the cytoplasm where it activates 
a number of substrates. It has been linked to the inside-out activation of integrins in 
endothelial cells  and fibroblasts, which in turn, mediates matrix assembly as well 
as regulating fibronectin assembly through the activation of α5β1 integrin.67 Akt has 
been shown to regulate the recycling of α5β1 integrin from the lagging edge to the 
lamellipodia in fibroblasts which leads to enhanced migration.67, 76 In a similar 
report, Akt knockout cells showed lower levels of proliferation as well as an 
impairment in migration and in extracellular matrix response.77 
 
1.4.2.3 β1 Integrin as a main mediator of cell migration 
Integrins are transmembrane receptors that mediate attachment between a cell and 
the tissues or cells surrounding it. They bind the surface of a cell to ECM 
components including fibronectin, laminin and collagen. They have a central role in 
signaling pathways that define the shape of the cell, the migration of the cell, and 
have been reported to help regulate the cell cycle.78-80 
The family of integrins contains 8 beta and 18 alpha subunits. As they are obligate 
heterodimers, the subunits assemble in pairs making up 24 distinct integrins 
combinations. Every integrin is comprised of the two subunits and will only 
recognize relatively short peptide motifs on their respective ligands. The 24 integrin 
combinations appear to have clear, non-redundant functions, shown through the 
generation of an extensive series of knockout mice.78  
Integrins perform outside-in signaling, but they also operate an inside-out signaling. 
This means that they are capable of transducing information from the ECM to the 
cell as well as reveal the status of the cell to the outside, allowing rapid and flexible 
responses to changes in the environment.78  Figure 1.8 shows a basic model of 
integrin structure and activation. 
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Figure 1.8:   Structure and activation of integrins 
 
Integrins consist of a 'head' region and two 'legs'. The heads contains a 'beta propeller' domain 
(alpha subunit) and a 'propeller-like' domain (beta subunit). A large interface between these two 
domains allows for stable association of heterodimer. In some alpha subunits, an I domain is 
inserted into the beta propeller domain and participates in promoting ligand binding (insert). The 
'legs' consist of tightly packed domains that form a rigid stalk with a flexible hinge region. Five cation-
binding sites are located within the head while a sixth one is present on the alpha subunit near the 
hinge region. The inactive, non-ligand occupied integrin is bent at the 'knee' region, and the 'head' 
domain faces down toward the membrane with the ligand-binding pocket in a low affinity 
conformation. The association of the alpha and beta cytoplasmic domains retains the integrin in the 
resting state. Talin binding to the beta cytoplasmic domain disrupts this alpha -beta cytoplasmic 
interaction, and triggers the inside-out conformational change leading to receptor activation. 
Activation is associated with slight shifting movement of the alpha and beta 'stalk' regions relative to 
each other, unbending (stretching) of the 'knee' region, and transition of the ligand-binding pocket 
into a high-affinity conformation.  
Image adapted from the Division of Experimental Oncology (Centre Pluridisciplinaire d'Oncologie 
Lausanne Cancer Center)  
 
In  breast cancer and several other tumor types, an over-expression of specific 
integrins has been linked to increased disease progression and decreased patient 
survival.62 α5β1 Integrin has been observed numerous times in a variety of cell 
lines, indicating that it is essential for binding to fibronectin. It potentially participates 
through binding with the FAK/PI3K/Akt cascade to regulate tumor cell migration as 
depicted in Figure 1.9.66, 78, 81-82 Moreover, Akt was shown to regulate the 
endocytosis and recycling of integrins through the phosphorylation of ACAP1. Upon 
phosphorylation by Akt, the ACAP1 binds directly to the β1 integrin on endosomal 
membranes to promote integrin recycling and therefore cell migration.64, 83  
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Figure 1.9:   Integrin regulation and recycling 
 
Growth factors  and integrin-ligand interactions regulate cell movement through various intracellular 
routes. The activation of growth factor receptors triggers intracellular signaling cascades, leading to 
the acitvation or inactivation of a variety of downstream molecules responsible for EMT. FAK 
activation by integrin-ligand interactions promotes PI3K/Akt signalling. The PI3K/Akt signalling 
pathway also promotes the recycling of integrins during cell migration via phosphorylation of ACAP1. 
Image adapted from P. Jian 2009.64  
 
The β1 integrin cytoplasmic domain contains five potential phosphorylation sites, of 
which the S785 site was shown to be essential for focal adhesion formation. 
Mulrooney et al.84 proposed a model for migration in which phosphorylation of β1 
integrin modulates the integrin-cytoskeleton interactions. In the dephosphorylated 
state, the β1 integrin is capable of interacting with the actin-based cytoskeleton and 
the focal adhesion proteins to create a focal adhesion site. They further proposed 
that phosphorylation of S785 on β1 integrin results in the breaking of this integrin-
cytoskeleton link. Migration is promoted in part by the dynamic regulation of the 
phosphorylation state of S785 which regulated the integrin actin connection and 
therefore alterations in this delicate cycle will disrupt normal cellular migration.84 
 
 
To sum up, deregulated metastatic pathways in cancer lead to a higher incidence of 
cancer mortality due to secondary tumors. New substances are desperately needed 
to specifically target the spread of tumors as well as to trigger the built in apoptotic 
pathways. So far, both 6BIO and 7BIO have turned out to be promising antitumor 
agents, with 6BIO showing strong effects against tumor metastasis. 
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2 AIMS OF THE STUDY 
Metasatic cancer is a horrific disease with little chance of a cure with available 
modern treatments. The small amount of research available for 6BIO and 7BIO 
indicate that they are potential candidates for clinical therapy, but further research is 
necessary to fully comprehend their anticancer abilities. 
To further elucidate the underlying mechanisms involved, the major goals of this 
study were as follows: 
a)  Antitumor activities of 6BIO and 7BIO 
For this aim a wide variety of in vitro assays were performed using FCM analysis to 
assess apoptosis and anoikis induction, as well as assays to monitor proliferation 
and viability upon exposure to the indirubin derivatives. 
 
b)  Effects of 6BIO and 7BIO on metastatic pathways 
For this aim a variety of migratory assays in response to different chemoattractants 
were performed including wound healing, TranswellTM migration and chemotaxis 
assays. Additionally, adhesion to fibronectin and invasive capabilities through 
MatrigelTM were assessed. 
 
c)  Effects of 6BIO on migratory signaling targets 
This aim was intended to look at which point the migratory signaling pathways were 
disrupted upon treatment with 6BIO. 
 
d)  Effects of 6BIO in different cell models 
As 6BIO has been shown to have varying effects based on the cell line, two tumor 
cell lines and a 3D spheroid model with both tumor spheroids and human fibroblast 
spheroids were utilized to evaluate the anti-migratory ability of 6BIO. 
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Study compounds: 6BIO and 7BIO  
6BIO and 7BIO used in the initial experiments were kindly provided by Dr. Meijer 
(Roscoff Biological Station in France, CNRS), and further investigations were 
performed with 6BIO and 7BIO purchased from Enzo Life Sciences (Farmingdale, 
NY).  Before stimulation, all substances were dissolved and further diluted in DMSO 
with final DMSO concentrations in all assays not exceeding 1%.  All 10 mM stock 
solutions and substances were stored at -20°C until use.  
3.1.2 Biochemicals, inhibitors, dyes and cell culture reagents 
Table 3.   Biochemicals, inhibitors, dyes and cell culture reagents 
 
Reagent 
 
Supplier 
Accustain® formaldehyde   Sigma-Aldrich, Taufkirchen, Germany 
Bradford ReagentTM   Bio-Rad, Munich, Germany 
Collagen G   Biochrome AG, Berlin, Germany Complete®   Roche Diagnostics, Penzberg, Germany 
DMSO  Roth GmbH, Karlsruhe, Germany 
DMEM   PAN Biotech, Aidenbach, Germany 
FCS gold   PAN Biotech, Aidenbach, Germany Glutimate  PAN Biotech, Aidenbach, Germany 
McCoys Medium   PAN Biotech, Aidenbach, Germany 
MatrigelTM   BD Discovery, Bedford, MA, USA 
MTT  Sigma-Aldrich, Taufkirchen, Germany 
NEAA  Invitrogen, Karlsruhe, Germany 
Page RulerTM Protein Ladder  Fermentas, St. Leon-Rot, Germany 
Penicillin  PAN Biotech, Aidenbach, Germany 
Polyacrylamide  Roth GmbH, Karlsruhe, Germany 
Propidium iodide  Sigma-Aldrich, Taufkirchen, Germany 
PermaFluor mounting medium   Beckman Coulter, Krefeld, Germany 
Pyruvate   Merck, Darmstadt, Germany 
Rhodamin-phalloidin   Invitrogen, Karlsruhe, Germany 
RPMI 1640  PAN Biotech, Aidenbach, Germany Streptomycin   PAN Biotech, Aidenbach, Germany 
Tris-HCl  Sigma-Aldrich, Taufkirchen, Germany 
Triton X-100   Merck, Darmstadt, Germany 
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Table 4.   Commonly used buffers 
 
Trypsin/EDTA (T/E) PBS (+) 
Trypsin 
 
0.5 g 
 
NaCl 
 
7.20 g 
EDTA 
 
0.2 g 
 
Na2HPO4 
 
1.48 g 
PBS 
 
1.0 L 
 
KH2PO4 
 
0.43 g 
H2O 
 
1.0 L, pH 7.4 MgCl2 x 6 H2O 0.10 g 
    
CaCl2 x 2 H2O 0.10 g 
    
H2O 
 
1.0 L, pH 7.4 
 
3.1.3 Technical equipment 
Table 5.   Technical equipment 
 
Name Device Producer 
Axioskop Upright microscope Zeiss Jena, Germany 
Culture flasks, plates, dishes Disposable cell culture 
material 
TPP 
Trasadigen, Switzerland 
Curix 60 Tabletop film processor Agfa Cologne, Germany 
Cyclone Storage Phosphor Screens Canberra-Packard Schwadorf, Austria 
FACSCalibur Flow cytometer Becton Dickinson Heidelberg, Germany 
IBIDITM µ-slide  Microscope slide IBIDI GmbH Munich, Germany 
LSM 510 Meta Confocal laser scanning 
microscope 
Zeiss 
Jena, Germany 
Mikro 22R Table centrifuge Hettich Tuttlingen, Germany 
Nanodrop® ND-1000 Spectrophotometer Peqlab Wilmington, DE, USA 
Nucleofector II Electroporation device Lonza GmbH Cologne, Germany 
Odyssey 2.1 Infrared Imaging System  LI-COR Biosciences Lincoln, NE USA 
Orion II Microplate 
Luminometer Luminescence 
Berthold Detection 
Systems 
Pforzheim, Germany 
Polytron PT1200 Ultrax homogenizer Kinematica AG Lucerne, Switzerland 
SpectraFluor PlusTM Microplate multifunction 
reader 
Tecan 
Männedorf, Austria 
SunriseTM Microplate absorbance 
reader 
Tecan 
Männedorf, Austria 
Vi-Cell™ XR Cell viability analyzer Beckman Coulter Fullerton, CA, USA 
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3.2 Methods 
3.2.1 Cell Culture  
3.2.1.1 Cell lines: Skbr3 and L3.6pl 
The human breast cancer cell line Skbr3 cells were a kind gift from Barbara Mayer 
(Department of Surgery, Klinikum Grosshadern, LMU Munich) and cultured with 
McCoys (PAA Laboratories, Coelbe, Germany), supplemented with 10% heat-
inactivated FCS gold (Biochrom AG, Berlin, Germany).  
The human pancreatic cancer cell line L3.6pl was generously provided by  
Christiane J. Bruns (Department of Surgery, Klinikum Grosshadern, LMU Munich) 
and cultured (37°C and 5% CO2) on Collagen G coated culture flasks with DMEM,  
supplemented with 10% heat inactivated FCS gold,  1x NEAA and 1 mM pyruvate.  
 
3.2.1.2 Cultivation of cell lines 
Cell lines were incubated at 37°C with 5% CO2 in a humidified incubator. The cells 
were cultivated as monolayers and split upon reaching 80% to 90% confluence.  
To split the cell lines, cells were rinsed one time using PBS and detached from the 
cell culture flasks using Trypsin/EDTA (T/E). The T/E reaction was stopped by 
adding growth medium to the cells and removed by centrifugation (1000 RPM, 5 
minutes, room temperature). Cells were resuspended in fresh medium and split 1:5 
for further cultivation or used for experiments. 
 
3.2.1.3 Freezing, thawing and long term storage 
To ensure similar experimental results, all cell lines were passaged no more than 
10 times before discarding and thawing a fresh stock. 
To freeze-back the cell lines, cells were harvested with T/E and resuspended in 
freezing medium (70% relative growth medium, 20% FCS, 10% DMSO) at a 
concentration of 2.0x 106 cells/ml and initially frozen in cryovials at -20°C for 24 
hours, and thereafter transferred to -80°C for short term storage or into liquid 
nitrogen for long term storage. The individual cryovials were rapidly thawed to room 
temperature and suspended in growth medium to reduce the amount of exposure to 
DMSO upon thawing. Cells were washed and centrifuged (1000 RPM, 5 minutes, 
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room temperature) before resuspending them in growth medium. Then they were 
cultivated for at least three days before splitting them for use in experiments.  
 
3.2.2 Flow cytometry 
Flow cytometry (FCM) is a technique used to count and examine microscopic 
particles, such as cells labeled with fluorescent tagged antibodies or stains (e.g. 
propidium iodide), by suspending them in a thin stream of fluid and passing them by 
an electronic detection apparatus. This technique allows simultaneous multi-
parametric analysis of the physical or chemical characteristics of thousands of 
particles per second. Based on these parameters, fluorescent-tagged antibodies or 
various stains can be utilized to measure apoptosis, cell cycle or expression and 
localization of antigens. 
 
3.2.2.1 Apoptosis analysis  
Quantification of apoptosis was performed according to Nicoletti et. al.85 Briefly, 1.5 
x 105 L3.6pl or Skbr3 cells were seeded per well into 24-well plates and allowed to 
adhere overnight. Growth medium was exchanged and cells were stimulated with 
desired substances for 24 or 48 hours, respectively. Cells were washed, trypsinized 
and resuspended before centrifugation for 10 minutes 600x g at 4° C. Samples 
were washed with PBS to remove remaining debris, centrifuged and resuspended 
in HFS buffer containing 2 mg/ml propidium iodide (PI). Stained cells were 
protected from light and incubated for at least 2 hours at 4°C. PI stained cells were 
detected by flow cytometry. 
Table 6.   Buffers for FCM analysis 
 
HFS Buffer FCM Buffer 
Na3-citrate 0.1% 0.10% NaCl 
 
8.12 g 
Triton-X 100 0.1% 0.10% KH2PO4 
 
0.26 g 
PBS 1 mL Na2HPO4  2.35 g 
    
KCl 
 
0.28 g 
    
Na2EDTA  0.36 g 
    
LiCl 
 
0.43 g 
    
Na-azide 
 
0.20 g 
    
H2O 
 
to 1 L, pH 7.4 
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3.2.2.2 Anoikis analysis 
Anoikis is a type of cell death that occurs when anchorage-dependent cells detach 
from the ECM. Anchorage-dependent cells remain adherent to the tissue to which 
they belong, allowing for communication between neighboring cells which provide 
essential growth or survival signals. Following cell-detachment from the ECM, cell-
matrix interactions are disrupted, typically resulting in anoikis. However, metastatic 
tumor cells evade anoikis induction to invade other tissues. 
Cell lines were prevented from adhering to the bottom of culture wells by culturing 
them in 24-well plates coated with polyHEMA as described by Bourguignon et al.86 
Briefly, cultures were trypsinized and plated at 0.75 x 105 cells per well onto 24-well 
polyHEMA-coated plates. PolyHEMA-coated plates contained 0.3 ml of 10 mg/ml 
solution of polyHEMA/ethanol per well and were dried overnight in the tissue culture 
hood. After appropriate time periods of growth in forced suspension, cells were 
harvested for apoptosis detection as described under section 3.2.2.1.  
3.2.2.3 Cell cycle analysis 
To analyze the cell cycle, the fluorescence intensity was measured in the 
logarithmic mode of the fluorescence channel 2 (FL2, em 585 nm) using a flow 
cytometer. Cells are treated using propidium iodide which intercalates into the DNA-
helix, the output of its fluorescence depends on the status of cellular chromatin.  
In the control cells, most of the cells are in the G0/G1 cell cycle phase with 2n 
chromosome set, lacking the sister chromatids. Cells found in the G2/M-phase are 
in the process of dividing, containing both the normal 2n chromosome set in 
addition to the duplicate sister chromatids. The duplication of chromatids allows for 
the G2/M-phase to be differentiated from the G0/G1-phase due to the higher 
fluorescence peak caused by the increased propidium iodide intercalation. Cells in 
the S-phase are undergoing synthesis wherein the chromatids are duplicated. The 
fluorescence peak of cells in the S-phase is found between the fluorescence peaks 
of G0/G1- and G2/M-phase. Finally in apoptotic cells, DNA is fragmented which 
generates a peak which is found to the left of the G0/G1 fluorescence. During 
graphical analysis, regions were gated for each fluorescence peak of the four 
enumerated chromatin states, and cells of each region were quantified using the 
Cell QuestTM software or by utilizing the cell cycle analysis program FlowJoTM. 
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3.2.2.4 β1 Integrin surface expression 
Surface expression of β1 integrin was measured using FCM analysis. 0.80 x 105 
Skbr3 cells were seeded and allowed to adhere for 8 hours before stimulation with 
6BIO for 30 minutes to 24 hours. Thereafter cells were harvested with Trypsin/ 
EDTA (T/E) and washed one time with PBS before blocking with 2% BSA for 15 
minutes at room temperature. Cells were incubated with the primary anti-β1 integrin 
antibody (Santa Cruz) for one hour at room temperature, washed one time with 
PBS and incubated with Alexa Fluor 488 goat-anti-mouse antibody (Molecular 
Signaling/Invitrogen) for 30 minutes at room temperature protected from light. Cells 
were washed one final time to remove unbound secondary antibody and re-
suspened in PBS containing 0.5% BSA and the fluorescence was read at 488 nm in 
the FACS machine immediately.  
 
3.2.3 Cell viability measurements 
The viability of cells was measured with the VI-CELLTM cell viability analyzer 
(Beckman Coulter, Krefeld, Germany) after exposure to 6BIO for 24 or 48 hours. 
Briefly, 1.5 x 105 Skbr3 cells were seeded in 24-well plates and allowed to adhere 
overnight before stimulating with 6BIO for 24 hours. Cells were harvested with T/E, 
resuspended in growth medium and read immediately in the VI-CELLTM.  
 
3.2.4 Proliferation 
1.5 x 103 Skbr3 or L3.6pl cells were seeded per well into 96-well plates. The next 
day, control cells were fixed and stained with crystal violet to determine the initial 
cell number. Then cells were treated with increasing concentrations of 6BIO or 
7BIO for 72 hours. After stimulation, cells were stained with crystal violet solution 
(0.5% crystal violet in 20% methanol) for 10 minutes. Unbound crystal violet was 
removed by rinsing with distilled water and cells were subsequently air-dried. Next, 
crystal violet which mainly binds to DNA was eluted from the cells with 0.1M sodium 
citrate in 50% ethanol. The absorbance of crystal violet is proportional to the cell 
number and was determined with the Sunrise ELISA reader (Tecan Trading AG, 
Maennedorf, Switzerland) at 550 nm. 
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3.2.5 Migration and invasion 
3.2.5.1 Wound healing assay 
1.5 x 105 Skbr3 or L3.6pl cells were seeded into 24-well plates and grown to 
confluence. A wound of approximately 1 mm was inflicted to each cell monolayer by 
scratching them with a yellow pipet tip. One PBS wash removed the detached cells 
before incubation for 16 hours at 37°C in either starvation medium (McCoys) or 
growth medium or growth medium with increasing concentrations of 6BIO. After 
incubation, cells were washed with PBS and fixed with 4% formaldehyde. One 
image per well was taken using an inverted light microscope using the Imago_QE 
camera system and the appending software (Till Photonics, Graefelfing, Germany). 
For quantification, these images were analyzed with S.CORE imaging analysis tool 
(S.CO LifeScience, Munich, Germany). This software tool identifies the cell covered 
area by using an algorithm based on brightness and contrast values. The cell-free 
area correlates to the ability of the cells to migrate into the wound. 
 
3.2.5.2 Migration through membranes 
Cellular migration through a 6.5 mm diameter tissue culture-treated polycarbonate 
membrane with 8 µM pores was assessed as follows: 1.0 x 105 cells were placed in 
the upper chamber of a TranswellTM unit containing serum-free medium with or 
without 6BIO. The lower chamber was pre-coated with collagen G and contained 
growth medium. Plates and inserts were incubated for 24 hours at 37°C (L3.6pl) or 
prestimulated with 6BIO for 20 hours and seeded into inserts for 4 hours (Skbr3). 
TranswellTM inserts were removed and stained with crystal violet. The cells that did 
not migrate from the upper chamber to the lower chamber were removed using a 
cotton swab and images were taken from each insert before the incorporated dye 
from the migratory cells was extracted with a 1:1 solution of 0.1M sodium citrate 
and 50% ethanol. The absorbance was measured at 550 nm in the Sunrise ELISA 
plate reader (Tecan Trading AG, Maennedorf, Switzerland).  
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3.2.5.3 Chemotaxis assay 
Chemotaxis of 6BIO-treated Skbr3 cells was investigated by the IBIDITM µ-slide 
(IBIDI, Martinsried, Germany). The chemotaxis assay was performed as described 
by the manufacturer. As seen in Figure 3.1, a Skbr3 suspension (7µl) of 5.0 x 106 
cells/ml was seeded into the center chamber of a µ-slide. The opposing medium 
reservoirs were filled with starvation medium and culture medium containing 10% 
FCS, respectively. The FCS diffuses linearly and in a stable manner, allowing for an 
FCS gradient from 0 to 10% in the seeding chamber of the µ-slide.  
 
Figure 3.1:   Chemotaxis assay in an IBIDITM µ-slide 
 
Images are taken from the IBIDI chemotaxis protocol:   
(A) Pictorial representation of the chemotaxis assay.  
(B) Graphical representation of cellular movements. 
 
Cell movement was recorded every 10 minutes over 24-hours by live cell imaging in 
a cell observation chamber (IBIDI) on the inverted light microscope using the 
Imago-QE camera system and Till photonics software. Cell tracking and analysis 
were done using the manual tracking plug-in (Fabrice Cordelieres, Orsay, France) 
and the chemotaxis and migration tool (IBIDI) for ImageJ (US National Institutes of 
Health, Bethesda, MD, USA), as described in the µ-slide chemotaxis protocol. The 
position of cells was defined as a point at low magnification from a 10x lens.  
10% FCS 0% FCS
Skbr3
y forward: yFMI =
yFMI 
accumulated distance
y center of mass : y= (1/n) S Endpoint y value
A
B
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3.2.5.4 MatrigelTM invasion assay 
Cellular invasion was measured using 6.5 mm diameter tissue culture-treated poly-
carbonate membrane with 8 µM pores (Costar). Membranes were coated with a 1:2 
dilution of MatrigelTM in medium according to manufacturer’s instructions.    
1.0 x 105 cells were placed in the upper chamber of the TranswellTM unit containing 
serum-free medium with or without 6BIO and lower chambers containing growth 
medium and fibronectin as an attractant. Skbr3 cells were allowed to invade for 20 
hours at 37°C. TranswellTM inserts were removed and stained with crystal violet. 
The cells that did not migrate from the upper chamber to the lower chamber were 
removed using a cotton swab and images were taken from each insert before the 
incorporated dye from the migratory cells was extracted with a 1:1 solution of 0.1M 
sodium citrate and 50% ethanol and the absorbance was measured at 550 nm in 
the Sunrise ELISA plate reader. Each assay was set up in duplicate and repeated 
at least three times. Images of invaded cells were analyzed using ImageJ software. 
 
3.2.6 Cell adhesion on fibronectin 
Cell adhesion was examined in 24-well plates coated with fibronectin. 1.0 x 105 
Skbr3 cells/well were allowed to adhere for 1.5 hours at 37°C. Wells were washed 
with PBS to remove any unbound cells and stained with crystal violet. Incorporated 
dye was extracted with a 1:1 solution of 0.1M sodium citrate and 50% ethanol and 
the absorbance was measured at 550 nm in the SunriseTM ELISA plate reader. 
 
3.2.7 Western blot 
3.2.7.1 Sample preparation 
For Western blot analysis, cell samples were washed 2x with ice-cold PBS following 
stimulation and were lysed by adding RIPA buffer to each sample well and frozen at 
-80°C. Next, cells were thawed on ice, and contents of triplicate wells were pooled 
into 1.5 ml reaction tubes. To remove all cellular debris, tubes were centrifuged for 
10 minutes at 10.000x g at 4°C. Supernatants were carefully transferred to a new 
reaction tube, and aliquots were taken for protein quantification (see 3.2.7.3).  
5x SDS-sample buffer was added to the lysates, mixed gently and boiled at 95°C 
for 5 minutes. All samples were stored at -20°C when not in use. 
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Table 7.   Buffers for preparation of total cell lysates 
 
RIPA Buffer 5x SDS-Sample Buffer 
Tris/HCl 0.79 g Tris/HCl 3.13 M pH 6.8 
NaCl 0.87 g  Glycerol 10 mL 
Nonidet NP 40 1.0 mL SDS 5.00% 
Deoxycholic acid 0.25 g DTT 2.00% 
SDS 0.10 g Pryonin Y 0.03% 
Complete® 1:25 H2O to 20 mL 
PMSF 1.0 mM 
 
Na3VO4 1.0 mM 
 NaF 1.0 mM 
 H2O to 100 mL 
 
 
3.2.7.2 Immunoprecipitation 
For evaluation of Rac1 levels, pull-down assays were performed using the 
Rac1/Cdc42 Activation Assay Kit 89856 (Pierce, Rockford, IL). Briefly, 1.0 x 105 
Skbr3 cells were seeded in triplicate into 24-well plates pre-coated with fibronectin 
and allowed to adhere for 1 hour. Cells were harvested with lysis buffer, pooled 
together and incubated with a Rhotekin RDB agarose slurry or GST human Pak1-
PDB for 1 hour at 4°C respectively. Samples were thoroughly washed and proteins 
were detected using Western blot analysis. Adjustment of the protein contents of 
respective samples was controlled by a Bradford-assay (see 3.2.7.3) prior to each 
Western blot. ImageJ (US National Institutes of Health, Bethesda, MD, USA) was 
used to quantify bands. 
 
3.2.7.3 Protein quantification 
Protein samples were quantified according to Bradford et al.87 The standard 
calibration curve was generated using samples containing defined concentrations of 
BSA suspended in H2O (50 g/ml – 500 g/ml). 190 l of the Bradford reagent 
(Bradford reagent stock was diluted 1:5 in H2O) was added to each 10 l aliquot of 
diluted protein samples (diluted 1:10 in H2O) and calibration samples in a 96-well 
flat bottom plate. All measurements were performed in duplicate. Probes were 
incubated for 5-10 minutes and the absorbance was measured in the SunriseTM 
ELISA reader. 
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3.2.7.4 SDS-PAGE 
SDS-PAGE according to Laemmli88 was performed by using the Mini Protean III 
system from Bio-Rad (Munich, Germany). Prior to loading the samples, the 
apparatus was assembled as described by the producer, and the chamber filled 
with chilled electrophoresis buffer. Equal protein concentrations of samples were 
loaded onto the SDS-gel and any empty slots were filled with an equal volume of 1x 
SDS-sample buffer. 1.5 µL of the Fermentas Page RulerTM Prestained Protein 
Ladder was loaded on each gel to estimate the molecular weights of the separated 
proteins. 
Table 8.   Buffers and gels for Western blotting 
 
 
 
 
3.2.7.5 Tank blotting 
After separating the proteins on a gel in the SDS-PAGE, proteins were transferred 
to a nitrocellulose membrane (Hybond-ECLTM, Amersham Bioscience, Freiburg, 
Germany) via standard tank blotting. A blotting sandwich was prepared in a box 
filled with 1x tank buffer to avoid bubbles as described by the producer. Prior to 
running the blot, all pads, papers, and membranes were equilibrated with 1x Tank 
buffer for at least 10 minutes. Membrane sandwiches were mounted in the Mini 
Trans-Blot® system (Bio-Rad, Munich, Germany). Ice-cold 1x Tank buffer was filled 
into the chamber and an ice pack was inserted to avoid excessive heat. Tank blots 
were carried out at 4°C, either at 100 V for 90 minutes or at 23 V overnight. 
Electrophoresis buffer 
Tris base   3.0 g 
Glycine 14.4 g 
SDS   1.0 g 
H2O to 1.0 L 
Stacking gel Separating gel
30 % PAA solution 1.28 mL 30 % PAA solution   5.0 mL 
1.25 M Tris/Hcl pH 6.8 0.75 mL 1.25 M Tris/Hcl pH 6.8 3.75 mL 
10 % SDS    75 µL 10 % SDS  150 µL 
H20 5.25 mL H20   6.1 mL 
APS    75 µL APS    75 µL 
TEMED    20 µL TEMED    20 µL 
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Table 9.   Tank buffer 
 
3.2.7.6 Detection 
Following the transfer, gels were stained in a Coomassie solution, and all 
membranes were washed once in TBS-T. Membranes were incubated in 5% Blotto 
or BSA to block unspecific binding followed by an overnight incubation period at 
4°C with the primary antibody dilution (Table 10). To remove all unbound primary 
antibody, all membranes were washed 4x in TBS-T prior to incubation for 1 hour 
protected from light at room temperature with the secondary antibody dilution 
(Table 11).  
Either of two detection methods was utilized to develop the membranes as 
described below: 
Detection method – LICOR: Secondary antibodies coupled to IRDyeTM 800 and 
Alexa Fluor® 680 with emission at 800 and 700 nm, respectively, were used. 
Membranes were incubated for 1 hour. Protein bands of interest were detected 
using the Odyssey imaging system (LICOR Biosciences, Lincoln, NE). Secondary 
antibodies used for this type of protein detection are listed in Table 11. After 
washing, membranes were scanned and analyzed, and proteins were quantified 
using the ImageJ gel analyzer plugin. 
Detection method – Enhanced Chemiluminescence: Membranes were incubated for 
2 hours with HRP-conjugated secondary antibodies (Table 11). For detection, 
luminol was used as a substrate. The membrane was incubated with ECL 
(enhanced chemiluminescence) solution for 1 minute (ECL Plus Western Blotting 
Detection Reagent RPN 2132, GE Healthcare, Munich, Germany). The appearing 
luminescence was detected by exposure of the membrane to an X-ray film (Super 
RX, Fuji, Düsseldorf, Germany) and subsequently developed with a Curix 60 
Developing system (Agfa-Gevaert AG, Cologne, Germany).  
5x Tank buffer 1x Tank buffer 
Tris base 15.2 g 5x Tank buffer 200 mL 
Glycine 79.2 g Methanol 200 mL 
H2O to 1.0 L H2O to 1.0 L 
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Table 10.   Primary antibodies 
 
Antigen Source Dilution In Provider 
-actin Mouse monocl. 1:1,000 Blotto 1% Chemicon 
Akt Rabbit polycl. 1:1,000 BSA 5% Cell Signaling 
phos.-AktS473 Mouse IgG2b 1:1,000 Blotto 5% Cell Signaling 
phos.-AktT308 Rabbit IgG 1:1,000 BSA 5% Cell Signaling 
β1 integrin Rabbit polycl. 1:1,000 Blotto 5% Cell Signallng 
phos-β1 IntegrinS785 Rabbit polycl. 1:500 BSA 5% Gen Way/Biozol 
phos.-ERKT202/Y204 Rabbit polycl. 1:1,000 BSA 5% Cell Signaling 
FAK Mouse monocl. 1:1,000 BSA 5% Santa Cruz 
phos.-FAKT397 Rabbit polycl. 1:500 BSA 5% Santa Cruz 
PI3K (p85) Rabbit polycl. 1:1,000 BSA 5% Upstate 
Rac1 Mouse monocl. 1:1,000 Blotto 5% Upstate 
 
 
Table 11.   Secondary antibodies 
 
Antibody Dilution In Provider 
Goat anti-mouse IgG1: HRP 1:1,000 Blotto 1% Biozol 
Goat anti mouse IgG: HRP 1:1,000 Blotto 1% Southern Biotech 
Goat anti-rabbit: HRP 1:1,000 Blotto 1% DiANOVA 
Alexa Fluor® 680 Goat-anti-mouse IgG 1:10,000 Blotto 1% Molecular Probes 
Alexa Fluor® 680 Goat-anti-rabbit IgG 1:10,000 Blotto 1% Molecular Probes 
IRDyeTM 800CW Goat-anti-mouse IgG 1:20,000 Blotto 1% LI-COR 
IRDyeTM 800CW Goat-anti-rabbit IgG 1:20,000 Blotto 1% LI-COR  
 
3.2.7.7 Staining of gels and membranes 
Gels were stained for 30 minutes in the Commassie staining solution and destained 
with the Coomassie destaining solution to control equal loading of the gel and the 
performance of the transfer. A 0.2% Ponceau S in 5.0% acetic acid solution was 
used to stain membranes. Destaining was performed in distilled water. 
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Table 12.  Gel staining solution 
 
 
3.2.8 Confocal laser scanning microscopy (CSLM) 
Cell imaging was assessed by seeding 0.2 - 1.0 x 105 Skbr3 cells in 8-well chamber 
glass sides (IBIDI) followed by stimulation with various concentrations of 6BIO for 
30 minutes to 24 hours. After three PBS washing steps, cells were fixed with 4% 
paraformaldehyde in PBS for 15 minutes at room temperature followed by 
permeabilization by incubating with .2% Trition X-100 in PBS for 2 minutes. Cells 
were blocked with 0.2% bovine serum albumin (BSA) and incubated with specific 
antibodies against Akt (Cell Signaling), pT308 Akt and pS473 Akt (Cell Signaling), 
Rac1 (Upstate), integrin 1 (Cell Signaling), pS785 integrin 1 (GenWay), FAK 
(Santa Cruz), and pT397 FAK for 1 hour. Specific proteins were visualized by 
secondary antibodies [Alexa Fluor 633-linked goat anti-mouse (Invitrogen) and 
Alexa Fluor 488-linked goat anti-rabbit (Invitrogen)]. Rhodamine phalloidin was 
used for F actin staining. PermaFluorTM mounting medium and individual coverslips 
were placed over each well for confocal microscopy. Split channel images were 
taken by Zeiss Meta confocal laser scanning microscopy (CSLM) with the 40x oil 
immersion lens. 
 
3.2.9 Skbr3 and fibroblast spheroids 
Spheroids are an important tool to evaluate the drug efficacy in that is well 
supported that they resemble real tissues more closely in structure and in functional 
properties.89 
3.2.9.1 Metabolic inhibition of Skbr3 spheroids 
In close collaboration with Dr. Barbara Mayer (SpheroTec, Martinsried, Germany), 
homotypic spheroids consisting either of Skbr3 tumor cells or fibroblasts were 
prepared according to the methodology of SpheroTec. Briefly, 96-well plates were 
coated with polyHEMA (Sigma Aldrich, Dreieich, Germany) to prevent attachment 
Coomassie Staining Solution Coomassie Destaining Solution 
Coomassie blue  3.0 g Glacial acetic acid 100 mL 
Glacial acetic acid 100 mL Ethanol 333 mL 
Ethanol 450 mL H20 to 1 L 
H20 to 1 L 
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of the tumor cells to the plastic dish. Multi-cellular spheroids were initiated from 
monolayer cultures treated with 1mM EDTA (Sigma), pH 7.2 at 37°C to prepare 
single-cell suspensions. After washing twice, cell viability was determined using the 
trypan blue exclusion test, and 5 x 104 viable cells in 100 µl cell culture medium 
supplemented with 10% FCS, 2% vitamine and 2% NEAA were plated in each well. 
This procedure resulted in a single multicellular spheroid per well.  
Orthotopic fibroblasts were prepared from human breast cancer samples by 
culturing minced tissue in DMEM/F12 medium supplemented with 10% FCS, 2% 
vitamin and 2% NEAA. Fibroblasts were cell-typed and used in early passages up 
to passage number 8. All cell culture products were purchased from PAN 
(Aidenbach, Germany). 
Mature Skbr3 spheroids were then examined over a 93-and a 165-hours period in 
individual wells of a 96-well plate in growth medium with or without increasing 
doses of 6BIO. Spheroids were then individually photographed before the addition 
of MTT/PMS (MTT: 2 mg/ml, PMS: 0.92 mg/ml). After 6 hours at 37°C in a 
humidified 5% CO2 atmosphere, the absorbance at 490 nm (reference wavelength 
650 nm) was measured with a 96-well plate ELISA reader (Tecan, Crailsheim, 
Germany). Three replicates per treatment were performed. 
 
3.2.9.2 Skbr3 spheroid confrontation with fibroblast spheroids 
The Skbr3 and fibroblast spheroids were cultivated as described above. Thereafter, 
individual spheroids of each type were confronted in individual wells containing 
growth medium with or without increasing doses of 6BIO for 48 hours. The degree 
of migration in the absence and presence of 6BIO was captured over time by 
microscopy (Zeiss, Jena, Germany). 
 
3.2.10   Statistical analysis 
All experiments were performed at least three times in triplicate unless otherwise 
noted. Results are expressed as mean value ± SEM. One-way ANOVA with Turkey 
post-tests or individual Students t-tests were performed using SigmaStat version 
3.5 for Windows or GraphPad PrismTM. P-values < 0.05 were considered significant.  
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4 RESULTS 
4.1 Antitumor effects of 6BIO and 7BIO in vitro 
Based on the promising preliminary results of the indirubin derivatives in the kinase 
assays by Zahler et al.11 we investigated the basic antitumor properties of 6BIO and 
7BIO in a variety of in vitro systems using the highly invasive breast cancer cell line 
Skbr3 and the pancreatic cell line L3.6pl.  
 
4.1.1 Effects of 6BIO and 7BIO on apoptosis 
The effects of 6BIO and 7BIO were assessed for the induction of apoptosis and on 
the cell cycle using flow cytometry. Tumor cells were stimulated with increasing 
doses of both substances and significant apoptosis was induced starting with 10 µM 
6BIO (approximately 39% Skbr3, 33% L3.6pl) and at least 30 µM 7BIO 
(approximately 38% Skbr3, 24% L3.6pl) for both cell lines (Figure 4.1).   
 
 
Figure 4.1:   Induction of apoptosis by indirubin derivatives 
 
Skbr3 (A) and L3.6pl (B) cells were seeded and allowed to adhere overnight before stimulation with 
increasing doses of BIO’s for 48 or 24-hours, respectively. One-way ANOVA/Turkey tests were used 
to assess significance. Bars represent +/- SEM from three independent experiments performed in 
triplicate.*, P <0.05  **, P<0.001. 
A)  Apoptosis induction in Skbr3
CO 3 10 30
0
20
40
60
80
% 
ap
op
to
tic
 
ce
lls
CO 3 10 30
0
20
40
60
80
%
 
ap
op
to
tic
 
ce
lls
6BIO 7BIO
6BIO (µM) 7BIO (µM)
**
*
CO 3 10 30
0
20
40
60
80
%
 
ap
op
to
tic
 
ce
lls
CO 3 10 30
0
20
40
60
80
% 
ap
op
to
tic
 
ce
lls
6BIO
7BIO (µM)
* *
7BIO
6BIO (µM)
**
B)  Apoptosis induction in L3.6pl
RESULTS 37 
 
 
4.1.2 Effects of 6BIO and 7BIO on anoikis induction 
Next, anoikis levels (or otherwise defined as levels of programmed cell death 
caused by anchorage independence) were similarly assessed via FCM analysis 
using PI staining as described in Materials and Methods.  
 
6BIO treatment and 7BIO treatment caused significantly varied effects in both cells 
lines. Skbr3 cells treated with 6BIO did not vary from controls with the exception of 
the 24-hour time point which showed a slight, but not significant reduction of anoikis 
(~12%) in comparison to the controls (~21%) (Figure 4.2). Skbr3 cells treated with 
7BIO showed no variance in anoikis induction until the 24-hour time point, where it 
slightly (~29%), but not significantly induced the amount anoikis (Figure 4.2A). 
L3.6pl cells treated with 6BIO showed increased anoikis after 8 hours (~12%) vs. 
control cells (~4%) and more significantly at 12 hours (~33% vs. control ~17%). 
7BIO treatment of L3.6pl also induced significant anoikis beginning at the 8-hour 
time point (~12% vs. control ~4%) and showing an even greater difference at 12 
hours (~29% vs. control ~17%) as seen in Figure 4.2B. 
 
 
 
 
Figure 4.2:   Mild anoikis-inducing effects of 6BIO and 7BIO 
 
Skbr3 (A) and L3.6pl (B) cells were seeded into polyHEMA coated 24-well plates as defined in 
Materials and Methods and stimulated with 10 µM of 6BIO or 7BIO or left untreated (Control) for up 
to 24 hours. One-way ANOVA/Turkey tests were used to assess significance. Bars are the SEM of 
three independent experiments performed in triplicate with *, P <0.05 and **, P <0.001. 
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4.1.3 Effects on tumor cell proliferation by 6BIO and 7BIO treatment 
Proliferation of both cell lines was significantly affected by treating the cells with the 
indirubin derivatives in comparison to the controls. Proliferation was assessed using 
crystal violet staining as described in Materials and Methods. It was dose-
dependently inhibited by increasing concentrations of both substances (Figure 4.3).  
Skbr3 cells (Figure 4.3A) treated with 6BIO showed a 76% (10 µM 6BIO) and a 
86% (30 µM 6BIO) as well as 57% (10 µM 7BIO) and an 84% (30 µM 7BIO) 
average decrease in proliferation in comparison to control wells.  
L3.6pl cells were affected at even lower doses, namely 50% at 1 µM, 70% at 3 µM 
and 78% at 10 µM 6BIO, as well as 55 % at 1 µM and approximately 76% at both 3 
and 10 µM 7BIO (Figure 4.3B). 
 
 
 
Figure 4.3:   Reduced tumor cell proliferation by BIO’s in a dose-dependent manner 
 
Skbr3 (A) and L3.6pl (B) cells were allowed to adhere for 24-hours prior to stimulation of cells with 
increasing doses of BIO’s or left untreated (Control). Cells were stained with crystal violet as 
described in Materials and Methods and the absorbance was calculated relative to the control wells. 
One-way ANOVA/Turkey tests were used to assess significance. Bars are the SEM of three 
independent experiments performed in triplicate with *, P <0.05 and **, P <0.001. 
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4.1.4 Effects of 6BIO on cell viability in Skbr3 breast cancer cells 
Skbr3 cells were seeded and allowed to adhere before stimulation with increasing 
doses of 6BIO and determination of cellular viability in the VI-CELLTM. Cellular 
viability was decreased with increasing concentrations of 6BIO (Figure 4.4). 
Reduction of Skbr3 viability was obvious beginning with 10 µM 6BIO (39% viable 
cells), and significant at 25 µM 6BIO treatment (72% viable cells) as well as highly 
significant at 50 µM 6BIO treatment (29% viable cells).  
 
 
 
Figure 4.4:   Significant effect on cellular viability by treatment with 6BIO 
 
Skbr3 cells were seeded and allowed to adhere before 24-hours of stimulation with increasing doses 
of 6BIO. Cells were harvested and measured using a VI-CELLTM. One-way ANOVA/Turkey tests 
were used to assess significance. Bars are the SEM of three independent experiments performed in 
triplicate with *, P <0.05 and **, P <0.001. 
 
4.1.5 Breakdown of cell cycle upon 6BIO treatment 
In order to understand the mechanism by which the 6BIO affects the cell growth, 
the cell cycle breakdown was analyzed. The cell cycle is composed of 4 distinct 
phases; G1 phase, S phase (synthesis), G2 phase (interphase) and M phase 
(mitosis). The DNA content of the cell varies upon which phase it is in, namely 
G1/G0 which have a haploid DNA content and G2 shows a diploid DNA content. 
Treatment with 6BIO arrested the cell in the S phase in Skbr3 cells and in the S 
phase/G2 phase for L3.6pl cells as seen in Figure 4.5. 
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Figure 4.5:  Effect of 6BIO treatment on the cell cycle 
 
Both cell lines were allowed to adhere overnight before stimulation with increasing doses of 6BIO or 
left as untreated controls (Control). Upper panels from Skbr3 (A) show an example set of histogram 
from the cell cycle distribution as quantified by the FlowJoTM. Lower panels from Skbr3 (B) and 
L3.6pl (C) show a graphical representation of the cell cycle breakdown from at least one data set. 
Experiments were performed three times in triplicate. 
 
 
 
Taken together, 6BIO and 7BIO show dose-and time-dependent antitumor activity 
through the induction of apoptosis and their effects on the cell cycle. Furthermore, 
they reduced both proliferation and viability of the tumor cells 
.  
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4.2 Different effects of 6BIO and 7BIO on metastatic pathways 
4.2.1 Impairment of wound healing by 6BIO treatment  
To initially assess the potential anti-migratory effects of the indirubin derivatives, 
wound healing assays were performed as outlined in Materials and Methods. 3 µM 
of both substances was selected as the dose to treat the cells with as this was a 
concentration low enough in both cells lines to have little to no effect on apoptosis 
or the cell cycle. Interestingly, 6BIO but not 7BIO significantly reduced the migration 
of both cell lines into the wounds. 6BIO reduced Skbr3 migration to about 13% of 
the control, whereas 7BIO allowed still 94% migration with respect to the control. 
(Figure 4.6A). L3.6pl cells were equally affected; with 6BIO treatment allowing for 
only 41% migration and 7BIO treatment for 86% respectively (Figure 4.6B). 
A      Wound healing assay in Skbr3 cells 
 
B     Wound healing assay in L3.6pl cells 
 
 
Figure 4.6:   Disruption of the wound closure ability by 6BIO 
 
Images on left: Representative images from triplicate experiments. Both cell lines were seeded and 
allowed to adhere as a confluent monolayer. This monolayer was wounded and treated with 3 µM 
6BIO or 7BIO or left untreated and allowed to close the wound for 16 hours (Skbr3) or 20 hours 
(L3.6pl). The cell covered area is shown in yellow, whereas gray indicates uncovered area.  
Graphs on right: The quantification is expressed as the percent migration related to untreated cells 
(control, 100%).  One-way ANOVA/Turkey tests were used to assess significance. Bars are the SEM 
of three independent experiments performed in triplicate with *, P <0.05 and **, P <0.001. 
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4.2.2 Effect of 6BIO on migration through TranswellTM inserts 
As 6BIO but not 7BIO was able to disrupt wound closure, its ability to block directed 
migration in response to chemoattractants in both cell lines was assessed. Skbr3 
cells were pre-treated with 3 µM 6BIO prior to seeding in the upper chamber of the 
TranswellTM insert. The cells completely migrated in less than 4 hours through the 
membrane towards the chemoattractant FCS in the lower chamber. L3.6pl cells 
were seeded in the upper chamber of the insert, stimulated with 3 µM 6BIO and 
allowed to migrate towards the FCS in the lower chamber for 20 hours. 6BIO 
significantly reduced the migration of Skbr3 cells through the 8 µM pores of the 
insert (Figure 4.7A) and visibly reduced L3.6pl migration, but not in any significant 
manner in comparison to the controls (Figure 4.7B).  
 
 
Figure 4.7:  Reduction of the tumor cell TranswellTM migration by 6BIO 
 
Skbr3 (A/B) and L3.6pl (C/D) tumor cells were allowed to migrate through 8 µM pores in a 
TranswellTM insert towards FCS in the presence or absence of 3 µM 6BIO treatment. Images on the 
left (A and C) are representative of migrated cells from triplicate experiments. Graphical analysis on 
the right (B and D) shows the quantification of migration relative to the control wells. One-way 
ANOVA/Turkey tests were used to assess significance. Bars are the SEM of three independent 
experiments performed in duplicate with *, P <0.05. 
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4.2.3 Effects of 6BIO on Skbr3 chemotaxis in response to a FCS gradient 
When presented to a FCS gradient (0-10%), Skbr3 cells will rapidly migrate towards 
the higher concentration. Skbr3 cells were seeded into an IBIDITM µ-slide and 
allowed to adhere before treatment with 6BIO. Thereafter, the cells migrated for a 
period of 24 hours. The directionality of 50 cells from individual assays were 
measured and expressed as y-forward values using ImageJ software. The controls 
were calculated as 1.0, and the y-forward index for the triplicate assays resulted in 
1.0 +/-0.264. The chemotaxis assays treated with 3 µM 6BIO showed a y-forward 
index of 0.367 +/-0.182. The ImageJ software was used to find the y-center of 
mass, the Euclidean distance (direct distance between the starting point and end 
point of a cell track), the accumulated distance, and the velocity at which the cells 
travel. 6BIO treatment impairs each of these in comparison to the control: y-center 
of mass (control 1.0 +/- 0.194 vs 6BIO 0.317 +/- 0.173), Euclidean distance (control 
1.0 +/- 0.100 vs 6BIO 0.630 +/- 0.078), accumulated distance (control 1.0 +/- 0.145 
vs 6BIO 0.743 +/- 0.065). In contrast, velocity was not targeted (control 1.0 +/- 
0.147 vs 6BIO 0.905 +/- 0.189) (Figure 4.8B). 
 
Figure 4.8:  Disruption of the directional cell migration by 6BIO 
 
Skbr3 directional migration was impaired in the presence of 6BIO in chemotaxis assays. Skbr3 cells 
migrated towards a 10% FCS gradient over a 24-hour period. 50 cells from each individual 
experiment were tracked and analyzed showing that treatment with 3 µM 6BIO induced a more 
random migration pattern (A). Graphical analyses of the parameters were calculated relative to the 
control set at a relative value of 1. One-way ANOVA/Students t-tests were used to assess 
significance. Bars are the SEM of three independent experiments with *, P <0.05.  
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4.2.4 Effects of 6BIO on Skbr3 invasion through MatrigelTM 
Untreated Skbr3 cells invade through MatrigelTM in response to FCS and fibronectin 
used as chemoattractants. Skbr3 cells were seeded into the upper well of a 
TranswellTM insert in the presence of 3 µM 6BIO and allowed to invade in response 
to chemoattractants for a period of 20 hours (Figure 4.9A). 3 µM 6BIO significantly 
disrupted the invasion of Skbr3 cells (59% relative invaded cells), nearly to that of 
the controls lacking any chemoattractants (55%) (Figure 4.9B). 
 
Figure 4.9:  Disruption of the Skbr3 invasion through MatrigelTM by 6BIO 
 
Skbr3 cells were seeded into the upper well of a TranswellTM insert and allowed to invade through a 
layer of MatrigelTM towards the lower chamber containing FCS and fibronectin (Control and 6BIO 
treated) or no attractants (Starvation). Representative images of invaded cells are shown (A).  The 
graph displays relative invasion of Skbr3 cells with the control cells set to 100% (B). One-way 
ANOVA/Turkey tests were used to assess significance. Bars are the SEM of three independent 
experiments performed in duplicate with *, P <0.05. 
 
4.2.5 Effect of 6BIO on tumor cell adhesion 
Cellular adhesion is a crucial step in tumor cell metastasis and this process can be 
up-regulated in circulating tumor cells. To test if 6BIO has any ability to block the 
adhesion of tumor cells, Skbr3 and L3.6pl cells were allowed to individually adhere 
for up to 1.5 hours to wells coated with various attractants (fibronectin, collagen G 
or MatrigelTM). Treatment with 6BIO did not significantly reduce the adhesion of 
L3.6pl to any of the coatings presented (Figure 4.10 A). Skbr3 cells were then 
tested with two different concentration of 6BIO against 5 µg/cm2 fibronectin coating. 
Treatment with 6BIO significantly reduced the ability of Skbr3 cells ability to bind to 
fibronectin by 23% (3 µM 6BIO) and 33% (10 µM 6BIO) respective to the controls 
(Figure 4.10 B).  
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A     L3.6pl 
 
B     Skbr3 
 
Figure 4.10:  Adhesion of tumor cells to attractants 
 
L3.6pl cells were seeded and allowed to adhere onto a variety of coated wells and simultaneously 
treated with 3 µM 6BIO or 7BIO. Neither 6BIO nor 7BIO significantly prevented L3.6pl from binding 
to any of the coatings with respect to the controls (A).  
Skbr3 cells were similarly seeded onto fibronectin-coated wells and stimulated with respective doses 
of 6BIO, clearly indicating a significant reduction of binding upon 6BIO treatment (B). 
One-way ANOVA/Turkey tests were used to assess significance. Bars are the SEM of three 
independent experiments performed in triplicate with *, P <0.05.  
 
 
 
 
 
 
Taken together, treatment with 6BIO, but not with 7BIO, at sub-apoptotic doses 
significantly reduced adhesion, wound healing capacity, directed migration and 
invasive capabilities of tumor cells. 
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4.3 β1 Integrin expression 
β1 Integrin is essential for adhesion and cell spreading thus playing a key role in 
migration signaling in tumor cells. α5β1 Integrin is reported to be necessary for 
binding to fibronectin.90-91 Since 6BIO significantly affected the binding of Skbr3 
cells to fibronectin (Figure 4.10), expression of β1 integrin was assessed.  
 
4.3.1 β1 Integrin expression on the Skbr3 cell surface 
Total β1 integrin surface expression was measured using specific primary anti-β1 
integrin antibodies (Santa Cruz) and secondary Alexa Fluor 488 goat-anti-mouse 
antibodies (Molecular Signaling/Invitrogen). Antibody-tagged cells were placed into 
the FACS machine and total mean fluorescence for each sample was measured. 
Two separate assays were preformed applying fibronectin to determine if β1 
integrin surface expression is disrupted.  
Initially, Skbr3 cells were allowed to adhere to fibronectin-coated plates as found in 
the adhesion assay (Figure 4.10) and assessed for β1 integrin surface expression 
(Figure 4.11 A and B).  
Next, Skbr3 cells were seeded and allowed to migrate over fibronectin for a period 
of 24 hours with or without 6BIO treatment and the total β1 integrin surface 
expression was assessed (Figure 4.11 C and D).  
In both experiments, no significant change of surface β1 integrin expression could 
be seen in comparison to control samples.  
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Figure 4.11:  Surface β1 integrin expression by 6BIO treatment 
 
Total β1 integrin expression was measured using specific antibodies toward β1 integrin applying 
FCM analysis of mean fluorescence for each sample. Skbr3 cells were allowed to adhere for 1 hour 
to fibronectin with or without 6BIO treatment as seen in the histograms (A) or graph (B). Skbr3 cells 
were allowed to migrate on fibronectin with or without 24-hours of 6BIO treatment as seen in the 
histograms (C) or in the graph (D).  
One-way ANOVA/Turkey tests were used to assess significance. Bars are the SEM of three 
independent experiments performed in triplicate. 
 
4.3.2 Total β1 integrin expression of Skbr3 cells 
The β1 integrin cycles within the cell as a necessary part of the focal adhesion 
turnover in the migratory process. Although they lack any known enzymatic activity 
of their own, integrins can initiate ‘outside-in signaling’ by recruiting signaling 
moieties to convey signals to the migratory machinery of the cell.65  
Although the external expression of β1 integrin remained the same (see 4.3.1), this 
does not account for the entire cycling process of β1 integrin. Therefore, expression 
of the activated and total form were assessed upon Skbr3 adhesion to fibronectin 
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with or without 6BIO treatment, applying Western blot and CSLM technology. Both 
assays utilized antibodies specific for the phosphorylation site S785 on α5β1 
integrin as well as the total form of β1 integrin.  
The expression of the total β1 integrin increased only slightly, whereas the 
phosphorylated form increased significantly in comparison to the controls (Figure 
4.12). Similar expression levels were seen using CSLM where total β1 integrin 
expression remained similar to that of control wells, but levels of pβ1 integrin S785  
were increased (Figure 4.13).  
 
Figure 4.12:  Expression of total β1 integrin by 6BIO treatment 
 
Skbr3 cells were seeded onto fibronectin coated wells and were allowed to adhere in the presence 
or absence (Control) of 6BIO for 1 hour. Western blot analysis of lysates from these samples were 
probed with antibodies against total β1 integrin and pS785 β1 integrin. Membranes representative 
from at least two independent experiments are depicted (left) and total protein relative to the controls 
were analyzed with the ImageJ gel analyzer plugin and represented graphically (right). One-way 
ANOVA/Turkey tests were used to assess significance. Bars are the SEM of three independent 
experiments performed in triplicate. * P<0.01. 
 
 
 
Figure 4.13:  Total and active β1 integrin expression after 6BIO treatment 
 
Skbr3 cells were seeded onto fibronectin-coated 8-well chamber slides and probed for total β1 
integrin expression (left) as well as for phospho β1 integrin S785 expression (right) with or without 
6BIO treatment.  Images are representative of at least two independent experiments. 
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4.4 Effects of 6BIO on migratory signaling pathways 
4.4.1 Alteration of Akt expression following 6BIO treatment 
Active Akt has been repeatedly shown to be necessary for the formation of focal 
adhesions in many tumor cells lines.64, 81 Akt is translocated to the plasma 
membrane upon PtdIns-3,4,5-P3 interaction, where it is then phosphorylated at two 
sites, first at T308 by PDK1 and then at S473 by PDK2.  
Based on the recent inverse kinase screening assay performed with 6BIO and 
7BIO, which indicated that PDK1 is a specific kinase target of 6BIO, but not of 
7BIO, both phosphorylation sites of Akt and the total form of Akt were probed with 
antibodies to determine if 6BIO or 7BIO had any effect (Figure 4.14).  
 
 
Figure 4.14:  Reduction of the activated form of Akt by 6BIO treatment 
 
Skbr3 cells were left untreated (CO) or treated with 10 µM 6BIO or 7BIO for 30 minutes. Active Akt 
expression was analyzed by Western blot. Equal protein loading was controlled by β-actin. 
Representative membranes are shown from triplicate experiments. 
 
 
CSLM was utilized to determine the location of the activated forms Akt using the 
pT308 antibody for the initial activation (Figure 4.15), and the pS473 antibody for 
the full activation (Figure 4.16). 
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Figure 4.15:  Reduction of active Akt localization to lamellipodia by 6BIO treatment 
 
Skbr3 cells were allowed to adhere to 8-well chamber slides prior to stimulation with 3 µM 6BIO for 
24 hours. Anti-pT308 Akt antibodies were used to tag active Akt which localizes to the lamellipodia. 
Images are representative of three independent experiments.  
 
 
 
Figure 4.16:  Reduction of pS473 Akt cycling by 6BIO treatment 
 
Skbr3 cells were treated with increasing doses of 6BIO or left untreated (Control) for 24 hours. 
Treatment by 6BIO significantly reduced the expression and location of pS473 in Skbr3 cells. CSLM 
images are representative of three independent experiments.  
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4.4.2 Erk and FAK levels following 6BIO treatment 
Erk and FAK play prominent roles in the signaling cascades of the migratory 
systems in tumor cells. Of the six phosphorylation sites on FAK, T397 is the auto- 
phosphorylation site required for catalytic activity of FAK.92 Once phosphorylated, 
FAK functions as an adapter protein along with integrins to recruit other adhesion 
and migratory signaling proteins to their regulators, thereby affecting the assembly 
and disassembly of FAs. FAK directly influences the activity of the Rho GTPase 
Rac1 through the phosphorylation of activators. Rac1 then activates the MAPK 
pathway, which in turn activates Erk. The activation of Erk is necessary for proper 
actin assembly, protrusive abilities and adhesion complex stability.80, 92-94  
Stimulation of Skbr3 cells with 3 µM 6BIO for 30-60 minutes did not affect the 
phosphorylation sites of Erk at either pT202 or pY204 (Figure 4.17A). This 
treatment also did not affect pT397 FAK or total FAK expression in Skbr3 cells 
(Figure 4.17B).  
 
Figure 4.17:  Effect on pErk or pFAK/total FAK expression in Skbr3 cells upon 6BIO treatment 
 
Skbr3 cells were seeded and allowed to adhere overnight before stimulation with or without 3 µM 
6BIO for 30 minutes and 1 hour before Western blot  analysis for the pT202/Y204 site for Erk, the 
pT397 FAK and total FAK. The pT202/y204 phosphorylation sites were unaffected by 6BIO 
treatment (A). pT397FAK and total FAK also showed no significant  changes from the control. 
Protein loading was controlled with β-actin. Images represent at least three independent 
experiments. 
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Total FAK in Skbr3 cells was imaged with CSLM after treatment with 6BIO for 24 
hours (Figure 4.18). In the CSLM images the total FAK expression within cells was 
not altered in 6BIO treated cells. However, the distribution of total FAK within the 
cell was disrupted. Furthermore, the cell morphology was disturbed showing fewer 
lamellipodia and FAK was significantly hindered from reaching focal adhesions 
upon 6BIO treatment.   
 
Figure 4.18:  Effect of 6BIO treatment on FAK expression and distribution 
 
Skbr3 cells were allowed to adhere prior to a 24-hour stimulation with or without increasing doses of 
6BIO. Cells were probed with a total FAK antibody and F actin was stained with rhodamine 
phalloidin before imaging with CSLM. White arrows indicate FAK expression either at focal 
adhesions or at lamellipodia. Images are representative of at least two independent experiments.  
 
4.5  Actin cytoskeleton signaling upon 6BIO treatment 
The constant cycling and remodeling of actin is necessary throughout the entire 
cellular migration process and is absolutely essential for the formation of filopodia, 
lamellipodia and stress fibers.59, 95 As demonstrated above, 6BIO has been shown 
to disrupt adhesion, migration and invasion of Skbr3 cells, all of which may depend 
on signaling cascades that are linked to actin.  
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To look now directly at the action of 6BIO against the actin cytoskeleton, migrating 
Skbr3 cells were fixed, stained for F actin with rhodamine phalloidin as well as 
probed over various time points with antibodies specific to Rho GTPase Rac1. 
4.5.1 Effects on the actin cytoskeleton by 6BIO treatment 
Initially, Skbr3 cells were grown in chamber slides and allowed to migrate over a 
24-hour time period in the presence of various concentrations of 6BIO. The actin 
cytoskeletons were stained with rhodamine phalloidin and changes in cellular 
morphology were noted after extended exposure to 6BIO. Control Skbr3 cells 
maintained a typical migrating cell morphology: Lamellipodia and filopodia could be 
found on the leading edge of migrating cells and cellular retraction occurred in the 
rear end of the cells. Skbr3 cells treated with 3 µM 6BIO showed distortions in the 
morphology: Fewer lamellipodia were visible and filopodia were longer and 
appeared to have difficulty in retracting. Treatment with 10 µM 6BIO showed even 
stronger effects: lamellipodia were nearly completely abolished and the cell took on 
a more spindle like appearance due to the number of filopodial extensions present 
(Figure 4.19).  
 
Figure 4.19:  Alteration of the actin cytoskeleton in Skbr3 cells upon 6BIO treatment 
 
Skbr3 cells were allowed to migrate for 24 hours in 8-well chamber glass slides with or without 
increasing 6BIO treatment before fixing and F actin staining with rhodamine phallodin. Cells were 
imaged with CLSM and the morphology of the fixed cells was assessed. 6BIO treatment caused 
large cellular protrusions (white arrows), a significant reduction in lamellipodia, and the cells took on 
a more spindle like morphology.  Representative images shown above represent migrating Skbr3 
cells from triplicate experiments stained with rhodamine phallodin for F actin.  
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4.5.2 Expression of Rac1 upon 6BIO treatment 
Based on the extreme distortion of the actin cytoskeleton in Figure 4.19, the small 
Rho GTPase Rac1 was investigated because it plays an essential role as a 
regulator of the actin cytoskeleton in migratory signaling.93 In detail, Rac1 is known 
to be a crucial regulator during lamellipodia and focal adhesion formation, as well to 
provide an essential signal required for the forward migration of moving cells.64  
The expression of the active form of this GTPase was investigated using a pull- 
down assay (Figure 4.20).  
 
 
Figure 4.20:  Effect of 6BIO treatment on active and total Rac1 expression 
 
The active form of Rac1 was measured using a pull-down assay  and Western blotting as described 
in Materials and Methods (A). The gel analyzer plugin for ImageJ was utilized to quantify the amount 
of active Rac1 (B). One-way ANOVA/Turkey tests were used to assess significance. Bars are the 
SEM of at least three independent experiments. 
 
 
 
Treatment by 6BIO visibly, but not significantly affected the active expression Rac1 
in Skbr3 cells. These findings were verified by CSLM staining (Figure 4.21). Since 
the lamellipodia were so clearly affected by 6BIO treatment as seen in Figure 4.19, 
Skbr3 cells were grown in 8-well fibronectin-coated slides for CSLM analysis and 
probed for Rac1 expression. It is known that the migratory signaling molecules must 
be constantly refreshed through their recycling through the cell. Skbr3 cells were 
probed for Rac1 to determine if this cycle is somehow disrupted by 6BIO treatment. 
Rac1 levels appeared similarly expressed in Skbr3 cells with or without 6BIO 
treatment. The amount of lamellipodia was reduced in 6BIO-treated cells, and the 
recycling of Rac1 is visibly disrupted as seen in Figure 4.21. 
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Figure 4.21:  Effect of 6BIO on Rac1 
 
Skbr3 cells were seeded thinly and allowed to adhere to fibronectin-coated 8-well chamber slides 
before 24 hours of treatment with 6BIO. Cells were fixed and probed with Rac1 antibodies and 
imaged with CSLM. Treatment  with 6BIO reduces lamelipodia  formation and white arrows indicate 
Rac1 located at the center of the cell, rather than at focal adhesion or the leading edge. Images are 
representative of three independent experiments performed in duplicate.  
 
 
4.6 Effects of 6BIO on 3D spheroids 
Skbr3 cells are quite amenable to spheroid formation, and it is well supported that 
3D spheroid potentially recreate the tumor microenvironment.89  
4.6.1 Disruption of Skbr3 and fibroblast spheroids 6BIO treatment 
For the evaluation of the 6BIO treatment on the spheroid structure, Skbr3 spheroids 
and fibroblast spheroids as well were cultivated. Spheroids were individually treated 
with a range of concentrations of 6BIO for up to 165 hours. 6BIO significantly 
disrupted the spheroids already at a 5 µM concentration (Figure 4.22).  
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Figure 4.22:  Images of Skbr3 spheroids treated with 6BIO 
 
Skbr3 spheroids were cultivated and treated for 165 hours with or without increasing doses of 6BIO. 
Spheroids were disrupted in a dose-dependent manner beginning with 5 µM of 6BIO. Images are 
representative of multiple images taken. 
 
 
Furthermore, MTT was added to the individual spheroids to measure their 
metabolic activities. Both spheroid types showed reduced metabolic activities in a 
dose-dependent manner (Figure 4.23).  
 
 
Figure 4.23:  Reduction of the metabolism of Skbr3 and fibroblast spheroids by 6BIO 
 
MTT was added to the Skbr3 spheroids (left) as well as to fibroblast spheroids (right) treated with 
increasing doses of 6BIO. The graphical analysis shows the results at 90 hours (T90 black) and 165 
hours (T165 white) of treatment with 6BIO in comparison to the well-known chemotherapeutic drug 
5-fluorouracil (5-FU). The effects of 6BIO on spheroid metabolism are dose-dependent .  
DMSO control 6BIO, 3µM
6BIO, 5µM 6BIO, 10µM
 1,04 mm
 0,44 mm  0,52 mm
 1,18 mm
SKBr -3, p40 Spheroids (S26) treated with 6BIO 
0%
20% 
40% 
60% 
80% 
100%
120%
Control 3µM 5µM 10µM 5-FU 10µM
6BIO concentration 
Fibroblasts 4277, p4 treated with 6BIO
0% 
20% 
40% 
60% 
80% 
100%
120%
Control 3µM 5µM 10µM 5-FU 10µM
6BiO concentration 
T90
T165
M
TS
 
(%
 
co
n
tro
l) 
M
TS
 
(%
 
co
n
tro
l) 
RESULTS 
 
 
4.6.2 Disruption of Skbr3 spheroid invasion by 6BIO
 in a confrontation assay
Skbr3 spheroids were challenged with fibroblast spheroids
confrontation assay as described in 
visibly reduced the migratory and invasive capabilities of Skbr3
the fibroblast spheroids. All
as can be seen in Figure 4.
When confronted, the Skbr3 cells clearly invade both themselves and the fibroblast 
spheroids, whereas the fibroblast spheroids remain separate throughout the entire 
experiment.  
 
Figure 4.24:  Reduction of migration and invasion of Skbr3 spheroids by 6BIO
 
Skbr3 spheroids (circled in red) and 
in individual wells in a 96-well plate. Skbr3 spheroids migrate and invade into 
spheroids (A) and into themselves (B), whereas the fibroblast 4277 P8 spheroids remain separate 
when confronted with another fibroblast (C)
dependent manner (D-F). The images shown are representative of a series of confrontations.
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5 DISCUSSION 
The main cause of cancer death is not due to the primary tumor itself, but to the 
metastasis thereof. By targeting these deregulated pathways with new chemo-
therapeutic drugs more effective treatment of the primary tumor can be realized, 
thereby allowing for a higher cancer eradication rate and potentially a better quality 
of life.  
In our study, two indirubin derivatives, namely 6BIO and 7BIO, show strong 
potential as anticancer agents, with 6BIO exhibiting highly specific antimetastatic 
activity through its interaction with PDK1 and the resulting regulation of Akt.  
 
5.1 Virtual comparison of 6BIO and 7BIO 
In recent years, protein kinases have proven themselves to be attractive targets for 
cancer therapeutics.1, 96 Although they are a promising category of anticancer 
drugs, kinase inhibitors are associated with many side effects due to their broad 
promiscuity of targets. This issue led to the inverse screening approach of several 
indirubin derivatives to predict their main target(s).11 6BIO and 7BIO are nearly 
identical derivatives of indirubin-3’-oxime, differing only in the location of the single 
bromine halogenation on the 6’ and 7’ carbon of the istatin ring respectively.31 This 
minute variation allows for astounding differences in their respective targets to elicit 
their antitumor activities.  
In the inverse kinase screening assay,11 it was revealed that 6BIO, but not 7BIO, 
was highly selective for the PDK1 kinase among other targets. Computer generated 
modeling studies clearly showed that PDK1 and 6BIO displayed perfect interaction 
geometries with the binding-pocket of PDK1 being easily able to accommodate the 
bromine atom. Contrary to this, 7BIO had poor interaction geometries with PDK1. 
To support these virtual predictions, a preliminary in vitro kinase assay specific for 
PDK1 showed that the IC50 value of 6BIO is 1.5 µM in comparison to 7BIO which 
ranked at > 100 µM.11  
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5.2 Antitumor activities of 6BIO and 7BIO 
To investigate the antitumor activities of the indirubin derivatives, two highly varied 
cell lines were selected: the breast cancer cell line Skbr3 and the pancreatic cell 
line L3.6pl. The indirubin derivatives induced apoptosis in both cell lines in a time-
and dose-dependent manner, with Skbr3 cells requiring a longer time period for the 
effects to be fully seen. When the cell lines were forced to remain in an anti-
adhesive state which mimics circulation throughout the body, both 6BIO and 7BIO 
showed anoikis-inducing effects. In addition, both 6BIO and 7BIO had very strong 
anti-proliferative properties, also occurring in a dose- and time-dependent manner.  
Thus, our data strongly confirmed the antitumor activities of 6BIO and 7BIO as 
predicted by results of Zahler et al.11 
 
5.3 Migration, invasion and adhesion are all disrupted       
after exposure to 6BIO or 7BIO 
Breast cancer is one of the leading causes of cancer death worldwide in women, 
but approximately only 6% of newly diagnosed patients will have either advanced or 
metastatic breast cancer. These statistics elevate to nearly 40% of patients who are 
initially diagnosed with the disease which will eventually progress to the metastatic 
form.97 Cancer metastasis comprises of a complex cascade of events, many of 
which require integrins, FAK, PDK1/Akt and actin to successfully execute signaling 
pathways in migration, adhesion and invasion.51, 80, 98 Therefore, single drug-based 
therapeutic interventions to avoid or to reduce metastasis are often quite inefficient. 
The inverse kinase screening assay indicated that 6BIO was highly selective for 
PDK1 and our in vitro assays support both 6BIO and 7BIO as antitumor agents.11 
PDK1 is ubiquitously expressed in mammalian tissues and plays a key role in the 
Akt signaling.70 Akt, which is activated upon PI3K activation, plays a crucial role in 
cell signaling pathways downstream of activated receptors located in focal contacts. 
Mounting evidence indicates that the PI3K-Akt signaling pathway promotes cell 
motility in tumor cells through its regulation of many signaling pathways and its link 
to the actin cytoskeleton.64   
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At sub-apoptotic doses 6BIO, but not 7BIO, significantly reduced the migration of 
both cell lines, nearly halting them completely in wound healing assays in vitro.  
Additionally, both the Skbr3 and the L3.6pl cells lost their ability to invade through 
membranes in response to chemoattractants. Chemotaxis of Skbr3 cells towards a 
gradient of FCS was dramatically disrupted upon 3 µM 6BIO treatment. The Skbr3 
cells showed significant disruption of their y-forward movement towards the 
chemoattractant gradient, indicating that cells were no longer able to polarize 
properly. The Euclidean distance and the total distance traveled by the Skbr3 cells 
were also significantly altered, indicating that the invasive signaling pathways were 
no longer functioning properly. Moreover, Skbr3 cells were highly impaired in their 
ability to invade through MatrigelTM layers in response to multiple chemoattractants.  
Finally, the adhesion of Skbr3 tumor cells to fibronectin was reduced through 6BIO 
stimulation. Taken together, these results indicate that 6BIO has very strong anti-
metastatic properties, which were not shown so far in the literature. 
 
5.4 β1 Integrin and the actin cytoskeleton 
Integrin-mediated migration is a complex process regulated by signaling cascades 
which control the actin cytoskeleton in response to microenvironmental signals to 
polarize the cell, extend the cellular membrane through protrusion and adhesion 
formations, translocate the cell body, and finally disassemble adhesions and rear 
retraction.79 Integrins are transmembrane receptors, mechanical links between 
extracellular signals, and the interior structural and signaling molecules which 
control the actin cytoskeleton.78  
β1 Integrin is essential for adhesion, cell spreading, and plays a key role in 
migration signaling in tumor cells. Although they lack any known enzymatic activity 
of their own, integrins can initiate ‘outside-in’ signaling by recruiting signaling 
moieties (such as FAK) that generate and convey signals to the migratory and 
proliferative machinery of the cell.65 Integrins are trafficked by the endosomal 
pathway and it is thought that these pathways and the recycling of integrins help to 
drive cell migration by moving adhesion receptors from the back to the front of 
moving cells.99 α5β1 Integrin is reported to be essential for binding of the cells to 
fibronectin.90-91  
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As 6BIO significantly affected the binding of Skbr3 cells to fibronectin (Figure 4.10), 
expression of β1 integrin was assessed, however the total form was not altered 
upon 6BIO treatment. In this context our experiments were unable to support the 
findings of Liu et al., which suggested β1 integrin as a downstream target of PDK1 
through Akt.10  
According to the research done by Mulrooney et al.,84 a decrease in the pS785 β1 
integrin promotes cell spreading and directed cell migration, whereas an increase in 
the pS785 β1 integrin enhances attachment but inhibits cell spreading or migration 
in teratocarcinoma cells. In our experiments, the effects of 6BIO treatment on Skbr3 
cells appeared to increase the total amount of pS785 β1 integrin, which coincides 
with the disruption of migration published by Mulrooney et al.84 
The actin cytoskeleton was clearly disrupted upon 24-hour stimulation with 6BIO. 
The cells took on a more spindle-like appearance, losing the rounded edges and 
many of the lamellipodia. They appeared to be unable to retract filopodia and 
recycle the actin components necessary for migration. The increased amount of 
pS785 β1 integrin and the ability of 6BIO to preferentially bind to PDK1, thereby 
lacking of full Akt activation are two of the most likely contributors to the disruption 
of the actin cytoskeleton.  
 
5.5 Metastatic signaling targets  
Several major signaling cascades are understood to be the main controlling factors 
in cellular adhesion and migration, which center around integrins, FAK and targets 
thereof. The major autophosphorylation site of FAK (Tyr-397) is the binding site for 
the SH2 domain of p85 and is responsible for the in vivo association of FAK with 
PI3K, which can subsequently activate PI3K during cell adhesion.100 FAK is also 
attributed to the recruitment and activation of signaling molecules (Cas-Crk-DOCK-
ELMO) which stimulate and localize activation of Rac1 and its effectors. Some of 
them are thought to be responsible for actin assembly, protrusive activity or 
modulation of the adhesion complex stability.92 Additionally, FAK is also directly 
linked to Erk through the activation of signaling molecules (Shc or Grb2), which 
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interact with Ras and Raf to phosphorylate and activate MAP kinase kinases 
(MEKs) which phosphorylate and activate Erk.94 This Raf/MEK/Erk cascade is 
directly responsible for regulating intra-nuclear transcription factors, thereby 
inducing cell migration and proliferation.101 
Recent reports suggest that PDK1, a well known upstream effector of Akt, plays a 
major role in breast cancer migration through the regulation of Akt signaling 
pathways involved in migration, including LIM kinase and cofilin which control actin 
polymerization.10, 69, 102 Through the regulation of β1 integrin adhesion as well as 
cellular migration are affected.10, 69, 83 Akt has been shown to be essential in 
endothelial cells and fibroblasts for the inside-out activation of fibronectin assembly 
through the activation of α5β1 integrin, which in turn, mediates matrix assembly.67 
6BIO treatment of the tumor cells did not affect the overall expression levels of Akt, 
but it did affect both of the phosphorylated forms of Akt. Immunohistochemistry 
results supported this finding, indicating that 6BIO blocks the activation of pT308 
Akt and thereby pS473 of Akt. Together, these observations support the data of the 
PDK1 kinase assay11 and our migratory data.  
Additionally, 6BIO did not strongly affect FAK, Rac1 or Erk. The active forms of 
these signaling molecules were not significantly altered upon 6BIO treatment. 
Immunohistochemistry results confirmed these findings, but also indicated that the 
metastatic signaling cycles were disrupted. FAK was no longer able to return to the 
cell front, and lamellipodia were unable to properly form. These signaling data 
suggest for the first time that 6BIO affects the metastatic signaling pathway through 
the regulation of Akt. 
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5.6 Effects of 6BIO on Skbr3 and fibroblast spheroids 
Spheroid cultures of cancer cells may better reflect characteristics of micro-
metastases than traditional monolayer cultures. Therefore, spheroids may be more 
convenient for cancer drug discovery as they quite accurately model the tumor 
microenvironment which leads to more relevant physiological out-comes.103-104  
Furthermore, low-passage cancer cell lines recapitulate the properties of the 
original tumor cells more closely than commonly used standard cell lines that 
experience artificial selection processes and mutations over years of passaging.104 
In our experiments, 6BIO reduced the metabolic capabilities of Skbr3 spheroids and 
fibroblast spheroids already at a 5 µM dose and caused the dissolution of spheroid 
structures at higher doses. Moreover, in a confrontation assay, Skbr3 spheroids 
were blocked from migrating and invading into fibroblast spheroids upon very low 
doses of 6BIO treatment, suggesting that 6BIO may also be highly effective in 
metastatic tumor models.  
 
 
 
 
Altogether, this study suggests that both 6BIO and 7BIO are strong antitumor 
candidates with different modes of action. 6BIO is especially of interest because it 
could be proven that the substance has significant anti-metastatic properties 
already at sub-apoptotic doses.  
Metastatic cancers are horrific diseases with little to no potential cures. However, 
our promising cell experimental data supports the further development of 6BIO as 
an anti-metastatic substance first for application in animal models and finally for 
clinical use.  
  
SUMMARY 64 
 
 
6 SUMMARY 
The presented work reports the following new findings with the experimental 
chemotherapeutic indirubin derivatives 6BIO and 7BIO: 
 
6BIO and 7BIO have antitumor properties  
Apoptosis induction was investigated in highly invasive breast adeno-carcinoma 
(Skbr3) and pancreatic tumor (L3.6pl) cell lines. In both cell lines, cell death could 
be induced proving the usability of 6BIO and 7BIO for cancer treatment. 
Interestingly, the mechanisms of action of these two substances indicate that they 
evoke cell death through different modes of action. Thus, these highly selective 
indirubin derivatives show strong potential as antitumor agents.  
 
6BIO, but not 7BIO, significantly affects metastatic pathways in tumor cells 
Astoundingly 6BIO, but not 7BIO, significantly reduced the migration of tumor cells, 
nearly halting them completely in the Skbr3 wound healing assay at sub-apoptotic 
doses. Chemotaxis was dramatically disrupted and tumor cells significantly lost 
their ability to invade through membranes or MatrigelTM layers in response to 
chemoattractants.  Additionally, adhesion of Skbr3 tumor cells to fibronectin was 
reduced by 6BIO application. Taken together, these results indicate that 6BIO has 
very strong anti-metastatic properties.   
 
Akt signaling is disrupted by 6BIO, but not by 7BIO 
PDK1 is a kinase target of 6BIO, but not of 7BIO, as seen in both the inverse kinase 
screening assay as well as in the in vitro kinase assay.11 By utilizing Western blot 
technology 6BIO, but not 7BIO, was shown to block the activation of Akt, the 
downstream target of PDK1. Additionally, CSLM technology clearly showed that the 
initial phosphorylation site pT308 of Akt is significantly down-regulated, and Akt was 
no longer able to translocate to the lamellipodia in migrating cells. Moreover, it 
could be proven that the second phosphorylation site, pS473 of Akt, was 
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significantly reduced in 6BIO-treated cells in comparison to control cells. 
Interestingly, treatment of migrating Skbr3 cells by 6BIO indicates that the reduction 
of dual-phosphorylated Akt severely affects the actin structure and the proper 
cycling of migratory signaling. 
 
Metastatic signaling and the actin cytoskeleton is affected by 6BIO treatment 
Rac1, FAK and Erk are all essential regulators of various components of the actin 
cytoskeleton in migrating tumor cells.59, 63-64, 92, 95, 105 First experiments indicated that 
6BIO does not immediately reduce any of these key signaling pathways upon 
adhesion or during migration of Skbr3 cells. Furthermore, the immunohistochemical 
results suggested that the metastatic signaling cascades are affected, and these 
signaling molecules are unable to properly cycle within the cell. The actin 
cytoskeleton was disrupted by treatment with 6BIO, resulting in a more spindle-like 
formation and significant reduction in lamellipodia.  
 
β1 Integrin is affected by 6BIO treatment 
β1 Integrin is essential in the formation of focal contacts and for the proper cycling 
of metastatic signaling. Treatment of Skbr3 cells with 6BIO disrupts this signaling 
and increases the amount of pS785 β1 found in the cells. An increase of pS785 has 
been linked to decreased motility in teratocarcinoma cells.84  
 
6BIO significantly affects Skbr3 and fibroblast spheroids 
Spheroids are considered to be very beneficial to cancer drug discovery as they 
more accurately model the tumor microenvironment which leads to more relevant 
physiological outcomes.103-104 6BIO reduced the metabolic capabilities of Skbr3 
spheroids and fibroblast spheroids already at low doses and caused the dissolution 
of spheroid structures at higher doses. Skbr3 spheroids were blocked from 
migrating and invading into fibroblast spheroids upon very low doses of 6BIO 
treatment, suggesting that 6BIO might also be highly effective in metastatic tumor 
models.  
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Taken together, the experimental indirubin derivatives 6BIO and 7BIO show strong 
potential as antitumor substances through completely different modes of action.  
6BIO especially is of note in that it is capable of inducing apoptosis, not only in 
arresting tumor cells, but it strongly inhibits tumor cell migration, invasion and 
adhesion, even at lower concentrations via interfering with a variety of metastatic 
signaling events as summarized in Figure 6.1 
Thereby this substance is suggested as a promising potential therapeutic agent in 
treatment of metastatic cancer.  
 
 
 
Figure 6.1:  Effects of 6BIO on metastatic signaling in tumor cells 
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